<?xml version="1.0" encoding="UTF-8"?><!-- generator="podbean/5.5" -->
<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
     xmlns:spotify="http://www.spotify.com/ns/rss"
     xmlns:podcast="https://podcastindex.org/namespace/1.0"
    xmlns:media="http://search.yahoo.com/mrss/">

<channel>
    <title>Talking Euretina</title>
    <atom:link href="https://feed.podbean.com/Euretinatalks/feed.xml" rel="self" type="application/rss+xml"/>
    <link>https://Euretinatalks.podbean.com</link>
    <description>Expert Discussions from the World of Retina: Exploring the latest developments in the field with world-renowned leaders. It will feature a monthly subspecialty journal club, panel discussions and interviews with key opinion  leaders.</description>
    <pubDate>Wed, 12 Aug 2026 05:01:00 +0100</pubDate>
    <generator>https://podbean.com/?v=5.5</generator>
    <language>en</language>
        <copyright>Copyright 2022 All rights reserved.</copyright>
    <category>Science</category>
    <ttl>1440</ttl>
    <itunes:type>episodic</itunes:type>
          <itunes:summary>Expert Discussions from the World of Retina: Exploring the latest developments in the field with world-renowned leaders. It will feature a monthly subspecialty journal club, panel discussions and interviews with key opinion  leaders.</itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
<itunes:category text="Science" />
<itunes:category text="Education" />
	<itunes:category text="Health &amp; Fitness">
		<itunes:category text="Medicine" />
	</itunes:category>
    <itunes:owner>
        <itunes:name>Whipsmart Media</itunes:name>
            </itunes:owner>
    	<itunes:block>No</itunes:block>
	<itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://pbcdn1.podbean.com/imglogo/image-logo/12977711/euretina_2000x2000px_72dpi_9ai67z.jpg" />
    <image>
        <url>https://pbcdn1.podbean.com/imglogo/image-logo/12977711/euretina_2000x2000px_72dpi_9ai67z.jpg</url>
        <title>Talking Euretina</title>
        <link>https://Euretinatalks.podbean.com</link>
        <width>144</width>
        <height>144</height>
    </image>
    <item>
        <title>Episode 86: The Dark Side of the Moon: Prof Frank Holz on Dry AMD and a Career in Retina</title>
        <itunes:title>Episode 86: The Dark Side of the Moon: Prof Frank Holz on Dry AMD and a Career in Retina</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-86-the-dark-side-of-the-moon-prof-frank-holz-on-dry-amd-and-a-career-in-retina/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-86-the-dark-side-of-the-moon-prof-frank-holz-on-dry-amd-and-a-career-in-retina/#comments</comments>        <pubDate>Wed, 12 Aug 2026 05:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/3ff3dd84-656f-347b-b8c4-6af0d3ca9516</guid>
                                    <description><![CDATA[<p>Ahead of his EURETINA Lecture in Vienna — "The Dark Side of the Moon: New Horizons in Dry AMD" — Past President Prof. Frank Holz joins President Prof. Nicole Eter for a wide-ranging conversation on his career, from pioneering retinal imaging to restoring central vision in advanced AMD, and why dry AMD may finally be at a turning point. Catch the lecture live in Vienna on Thursday 1 October</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ahead of his EURETINA Lecture in Vienna — "The Dark Side of the Moon: New Horizons in Dry AMD" — Past President Prof. Frank Holz joins President Prof. Nicole Eter for a wide-ranging conversation on his career, from pioneering retinal imaging to restoring central vision in advanced AMD, and why dry AMD may finally be at a turning point. Catch the lecture live in Vienna on Thursday 1 October</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/6fpiqp27i99nmv7a/Ep_86_Draft_29q0k0.mp3" length="16047360" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ahead of his EURETINA Lecture in Vienna — "The Dark Side of the Moon: New Horizons in Dry AMD" — Past President Prof. Frank Holz joins President Prof. Nicole Eter for a wide-ranging conversation on his career, from pioneering retinal imaging to restoring central vision in advanced AMD, and why dry AMD may finally be at a turning point. Catch the lecture live in Vienna on Thursday 1 October]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1002</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>86</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 85: Masquerade Syndromes: When Uveitis Isn't Uveitis</title>
        <itunes:title>Episode 85: Masquerade Syndromes: When Uveitis Isn't Uveitis</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-85-masquerade-syndromes-when-uveitis-isnt-uveitis/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-85-masquerade-syndromes-when-uveitis-isnt-uveitis/#comments</comments>        <pubDate>Mon, 03 Aug 2026 18:53:53 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/81e0428a-cded-3f9d-a5f1-6af3cb66ecaa</guid>
                                    <description><![CDATA[<p>In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Prof Bahram Bodaghi is joined by Prof Elisabetta Miserocchi and Prof Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Prof Bahram Bodaghi is joined by Prof Elisabetta Miserocchi and Prof Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/cuijpwr76auvnga3/Ep_85_Draft_27319w.mp3" length="33131136" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Prof Bahram Bodaghi is joined by Prof Elisabetta Miserocchi and Prof Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2070</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>85</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 84: Inside Euretina Innovation Spotlight: Retina, Industry &amp; Regulators</title>
        <itunes:title>Episode 84: Inside Euretina Innovation Spotlight: Retina, Industry &amp; Regulators</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-84-inside-euretina-innovation-spotlight-retina-industry-regulators/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-84-inside-euretina-innovation-spotlight-retina-industry-regulators/#comments</comments>        <pubDate>Tue, 21 Jul 2026 11:01:53 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/073677ae-cd33-34e1-84f5-584c8edbb908</guid>
                                    <description><![CDATA[<p>The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA's Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can't offer</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA's Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can't offer</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/pu2gtce4gity24dc/Ep_84_Draft_29hzby.mp3" length="12631296" type="audio/mpeg"/>
        <itunes:summary><![CDATA[The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA's Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can't offer]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>789</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>84</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 83: Retinopathy of Prematurity: Has Anti-VEGF Changed the Game?</title>
        <itunes:title>Episode 83: Retinopathy of Prematurity: Has Anti-VEGF Changed the Game?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-83-retinopathy-of-prematurity-has-anti-vegf-changed-the-game/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-83-retinopathy-of-prematurity-has-anti-vegf-changed-the-game/#comments</comments>        <pubDate>Tue, 14 Jul 2026 00:24:38 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/4539ab72-72e1-3516-9be9-c2d10816ade0</guid>
                                    <description><![CDATA[<p>Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/uurhm7gnc2gmuaie/Ep_83_Draft_27i2q5.mp3" length="30026439" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1885</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>83</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 82: Uveal Melanoma in Pregnancy: To Treat or to Wait?</title>
        <itunes:title>Episode 82: Uveal Melanoma in Pregnancy: To Treat or to Wait?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-82-uveal-melanoma-in-pregnancy-to-treat-or-to-wait/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-82-uveal-melanoma-in-pregnancy-to-treat-or-to-wait/#comments</comments>        <pubDate>Fri, 26 Jun 2026 05:10:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/0dd92a31-70eb-308d-8a43-fd48b5276171</guid>
                                    <description><![CDATA[<p>A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/by3anukk4fvxcq4h/Ep_82_Draft_29jgjp.mp3" length="16092288" type="audio/mpeg"/>
        <itunes:summary><![CDATA[A diagnosis of uveal melanoma during pregnancy forces an agonising question: treat now, or wait? Dr Emine Kiliç chairs a multidisciplinary discussion with Dr Iwona Rospond-Kubiak (Poznań), Prof. Antonia Joussen (Charité, Berlin) and radiation oncologist Dr Adam Chicheł on plaque brachytherapy and fetal radiation exposure, how gestational age shapes timing, and the reassuring — if limited — evidence on placental spread and maternal survival.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1005</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>82</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 81: The Women in Retina survey - 5 years on</title>
        <itunes:title>Episode 81: The Women in Retina survey - 5 years on</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-81-the-women-in-retina-survey-5-years-on/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-81-the-women-in-retina-survey-5-years-on/#comments</comments>        <pubDate>Wed, 17 Jun 2026 09:19:39 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/5110e868-a444-3b3b-bc41-020c65b6d9ff</guid>
                                    <description><![CDATA[<p>Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/28q2mdcdzdbrd6vr/Ep_81_Draft_26s94r.mp3" length="21091200" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Euretina will shortly relaunch the Women in Retina survey, building on the first dataset. In this podcast, Prof. Anat Loewenstein, Dr Federica Fossataro and Prof. Nicole Eter explore what has changed since the original 2021 study, what's new and why participation from the whole community - women and men alike - is essential to measuring real progress. The Women In Retina Initiative is sponsored by Bayer.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1318</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>81</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 80: Geographic Atrophy: Rethinking Endpoints and Real-World Impact</title>
        <itunes:title>Episode 80: Geographic Atrophy: Rethinking Endpoints and Real-World Impact</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-80-geographic-atrophy-rethinking-endpoints-and-real-world-impact/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-80-geographic-atrophy-rethinking-endpoints-and-real-world-impact/#comments</comments>        <pubDate>Sat, 02 May 2026 06:16:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/8cc26b59-b0b0-3d6e-a1bc-2c963cd8c973</guid>
                                    <description><![CDATA[<p>New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/m48f5n4quqv9tp7n/Ep_80_Draft_28fr55.mp3" length="33544320" type="audio/mpeg"/>
        <itunes:summary><![CDATA[New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein is joined by Sobha Sivaprasad and Kristina Pfau to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2096</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>80</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 79: Decoding Stargardt: New Treatments, Genetics, and What Lies Ahead</title>
        <itunes:title>Episode 79: Decoding Stargardt: New Treatments, Genetics, and What Lies Ahead</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-79-decoding-stargardt-new-treatments-genetics-and-what-lies-ahead/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-79-decoding-stargardt-new-treatments-genetics-and-what-lies-ahead/#comments</comments>        <pubDate>Wed, 01 Apr 2026 05:05:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/cfb4b366-3561-3925-8de5-27ca200748a6</guid>
                                    <description><![CDATA[<p>A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/8xu3s8esepdy88a3/Ep_79_Draft_28ehvn.mp3" length="33790464" type="audio/mpeg"/>
        <itunes:summary><![CDATA[A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2111</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>79</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 78: Insights from the EURETINA Mentorship Programme</title>
        <itunes:title>Episode 78: Insights from the EURETINA Mentorship Programme</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-78-insights-from-the-euretina-mentorship-programme/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-78-insights-from-the-euretina-mentorship-programme/#comments</comments>        <pubDate>Mon, 16 Mar 2026 05:10:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/96f162db-25ac-3d67-ad16-15007b1dc2a9</guid>
                                    <description><![CDATA[<p>Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/9ns7uqwvm9ekavap/Ep_78_Draft_27h8q0.mp3" length="18967680" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Three former mentees of the EURETINA Mentorship Programme share how the initiative helped shape their careers in retinal research and clinical practice. Özge Yanık Odabaş, Karolina Motloch and Omer Trivizki discuss mentorship, international collaboration, and the opportunities created through the programme’s growing alumni network. Their experiences highlight how structured mentorship can accelerate professional development for the next generation of retina specialists]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1185</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>78</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 77: Implementing AI in Retina Practice: From Screening to Decision Support</title>
        <itunes:title>Episode 77: Implementing AI in Retina Practice: From Screening to Decision Support</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-77-implementing-ai-in-retina-practice-from-screening-to-decision-support/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-77-implementing-ai-in-retina-practice-from-screening-to-decision-support/#comments</comments>        <pubDate>Thu, 05 Mar 2026 05:02:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/2652146f-7ea4-331e-8d87-a13eed49abc2</guid>
                                    <description><![CDATA[<p>Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/f2h7wvrqxwtpzecf/Ep_77_Draft_28jrf8.mp3" length="35543040" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Artificial intelligence is rapidly reshaping retina care — but where does it truly add value in daily practice? Professors Tien Wong and Daniel Ting join Stela Vujosevic to explore how AI is moving beyond screening into risk stratification, clinical decision support, and home monitoring. From infrastructure challenges to real-world implementation, this episode offers practical insights for retina specialists preparing for an AI-enabled future]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2221</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>77</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 76: AI in Diabetic Retinopathy: Screening, Biomarkers and What Comes Next</title>
        <itunes:title>Episode 76: AI in Diabetic Retinopathy: Screening, Biomarkers and What Comes Next</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-76-ai-in-diabetic-retinopathy-screening-biomarkers-and-what-comes-next/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-76-ai-in-diabetic-retinopathy-screening-biomarkers-and-what-comes-next/#comments</comments>        <pubDate>Wed, 11 Feb 2026 09:17:07 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/9a7a6a4b-798e-303c-a784-60c43cd71383</guid>
                                    <description><![CDATA[<p>Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/dgy93pb29mnbktmh/Ep_76_Draft_28ggd2.mp3" length="29544192" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Artificial intelligence is rapidly reshaping how we screen, classify, and treat diabetic retinal disease. Professor Aude Couturier, Professor Edoardo Midena, and Professor Reinier Schlingemann discuss real-world AI applications in diabetic retinopathy — from population screening and imaging biomarkers to phenotyping and precision treatment in diabetic macular oedema]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1846</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>76</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 75:  Transitioning from Retina Specialist to Industry</title>
        <itunes:title>Episode 75:  Transitioning from Retina Specialist to Industry</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-75-crossing-the-divide-retina-specialists-moving-from-clinic-to-industry/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-75-crossing-the-divide-retina-specialists-moving-from-clinic-to-industry/#comments</comments>        <pubDate>Mon, 19 Jan 2026 05:01:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/bd049076-c780-3cff-9a90-b94cbe4d61d6</guid>
                                    <description><![CDATA[<p>What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/kshvhj9gis69s48g/Ep_75_Draft_28i3hs.mp3" length="31048320" type="audio/mpeg"/>
        <itunes:summary><![CDATA[What drives leading retina specialists to trade the clinic for corporate innovation? In this episode, Euretina Board member Kourous Rezaei speaks with Jay Duker (CEO, Eyepoint), Sascha Fauser (SVP, Roche), and Marion Munk (CSO, Gutblick Group; CMO, Isarna Therapeutics) about their transitions from clinical practice to industry. Together they share insights on leadership, research, and the evolving relationship between academia and biotechnology in shaping the future of retinal therapeutics]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1940</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>75</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 74: Intuition in Uncharted Waters: The Art of Retinal Surgery</title>
        <itunes:title>Episode 74: Intuition in Uncharted Waters: The Art of Retinal Surgery</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-74-operating-in-unchartered-territory-the-intuitive-surgeon/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-74-operating-in-unchartered-territory-the-intuitive-surgeon/#comments</comments>        <pubDate>Wed, 17 Dec 2025 22:57:24 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/c0d43077-348b-3a26-900b-2a9612f17a32</guid>
                                    <description><![CDATA[<p>In this episode Professors Dean Eliott, Grazia Pertile, and José García-Arumí join chair Kourous Rezaei to explore how surgical mastery is built through intuition, preparation, and reflection. They share practical insights on mentorship, focus, teamwork, and managing stressful cases — from avoiding coffee before surgery to resetting after complications — revealing that great surgeons are defined not just by skill, but by judgment, patience, and care for the patient</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode Professors Dean Eliott, Grazia Pertile, and José García-Arumí join chair Kourous Rezaei to explore how surgical mastery is built through intuition, preparation, and reflection. They share practical insights on mentorship, focus, teamwork, and managing stressful cases — from avoiding coffee before surgery to resetting after complications — revealing that great surgeons are defined not just by skill, but by judgment, patience, and care for the patient</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/mci6fwx9rqgyemdc/Ep_74_Draft_2625yb.mp3" length="37951872" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode Professors Dean Eliott, Grazia Pertile, and José García-Arumí join chair Kourous Rezaei to explore how surgical mastery is built through intuition, preparation, and reflection. They share practical insights on mentorship, focus, teamwork, and managing stressful cases — from avoiding coffee before surgery to resetting after complications — revealing that great surgeons are defined not just by skill, but by judgment, patience, and care for the patient]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2371</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>74</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 73: When to Treat Small Choroidal Melanomas: A Debate Between Early Intervention and Observation</title>
        <itunes:title>Episode 73: When to Treat Small Choroidal Melanomas: A Debate Between Early Intervention and Observation</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-73-when-to-treat-small-choroidal-melanomas-a-debate-between-early-intervention-and-observation/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-73-when-to-treat-small-choroidal-melanomas-a-debate-between-early-intervention-and-observation/#comments</comments>        <pubDate>Tue, 09 Dec 2025 10:59:48 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/1092a3bb-91f9-305d-a1dc-20362e32b93f</guid>
                                    <description><![CDATA[<p>In this first-ever debate edition of Talking Euretina, Dr Rumana Hussain (Liverpool Ocular Oncology Centre) introduces Professors Arun Singh (Cole Eye Institute, Cleveland Clinic), Heinrich Heimann (Liverpool Ocular Oncology Service) and Bertil Damato (Moorfields Eye Hospital) as they debate one of ocular oncology’s most enduring questions — when to operate on small choroidal melanomas. The panel examines diagnostic uncertainty, genetic risk and patient choice in determining when to treat.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this first-ever debate edition of <em>Talking Euretina</em>, Dr Rumana Hussain (Liverpool Ocular Oncology Centre) introduces Professors Arun Singh (Cole Eye Institute, Cleveland Clinic), Heinrich Heimann (Liverpool Ocular Oncology Service) and Bertil Damato (Moorfields Eye Hospital) as they debate one of ocular oncology’s most enduring questions — when to operate on small choroidal melanomas. The panel examines diagnostic uncertainty, genetic risk and patient choice in determining when to treat.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/6jaqfrhr6yd5juip/Ep_73_Draft_27c1ko.mp3" length="28414080" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this first-ever debate edition of Talking Euretina, Dr Rumana Hussain (Liverpool Ocular Oncology Centre) introduces Professors Arun Singh (Cole Eye Institute, Cleveland Clinic), Heinrich Heimann (Liverpool Ocular Oncology Service) and Bertil Damato (Moorfields Eye Hospital) as they debate one of ocular oncology’s most enduring questions — when to operate on small choroidal melanomas. The panel examines diagnostic uncertainty, genetic risk and patient choice in determining when to treat.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1775</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>73</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 72: Bridging the Gap - Why Diversity in Retina Trials Can’t Wait</title>
        <itunes:title>Episode 72: Bridging the Gap - Why Diversity in Retina Trials Can’t Wait</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-72-bridging-the-gap-why-diversity-in-retina-trials-can-t-wait/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-72-bridging-the-gap-why-diversity-in-retina-trials-can-t-wait/#comments</comments>        <pubDate>Thu, 27 Nov 2025 05:50:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/53fb1c1f-30da-3be2-81eb-46136cebaee1</guid>
                                    <description><![CDATA[<p>Retinal diseases disproportionately affect certain populations—yet these groups are underrepresented in research. In this episode, Dr. Christiana Dinah chairs a global panel including Drs. Adrienne Scott, Charles Wykoff and Jeremiah Brown to explore the systemic and structural barriers to inclusion in retina trials, and why the stakes for equity have never been higher</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Retinal diseases disproportionately affect certain populations—yet these groups are underrepresented in research. In this episode, Dr. Christiana Dinah chairs a global panel including Drs. Adrienne Scott, Charles Wykoff and Jeremiah Brown to explore the systemic and structural barriers to inclusion in retina trials, and why the stakes for equity have never been higher</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/y5s2vanpmvqzwzae/Ep_72_Draft_27cf5b.mp3" length="40544256" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Retinal diseases disproportionately affect certain populations—yet these groups are underrepresented in research. In this episode, Dr. Christiana Dinah chairs a global panel including Drs. Adrienne Scott, Charles Wykoff and Jeremiah Brown to explore the systemic and structural barriers to inclusion in retina trials, and why the stakes for equity have never been higher]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2533</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>72</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 71: Restoring Vision with Bionics: Inside the Prima Implant Breakthrough</title>
        <itunes:title>Episode 71: Restoring Vision with Bionics: Inside the Prima Implant Breakthrough</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-71-restoring-vision-with-bionics-inside-the-prima-implant-breakthrough/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-71-restoring-vision-with-bionics-inside-the-prima-implant-breakthrough/#comments</comments>        <pubDate>Mon, 10 Nov 2025 21:53:50 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/cb7f6fb7-26a9-324f-87e0-3d8c7acefe9b</guid>
                                    <description><![CDATA[<p>In this episode, Prof. Frank Holz leads a panel discussion on a major leap forward in retinal prosthesis: the Prima system for geographic atrophy. Joined by Dr. Mahi Muqit and Prof. Lars-Olof Hattenbach, they explore how their extraordinary wireless subretinal implant is restoring visual perception in late-stage AMD. </p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Prof. Frank Holz leads a panel discussion on a major leap forward in retinal prosthesis: the Prima system for geographic atrophy. Joined by Dr. Mahi Muqit and Prof. Lars-Olof Hattenbach, they explore how their extraordinary wireless subretinal implant is restoring visual perception in late-stage AMD. </p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/smkwp35vh7jzpdmg/Ep_71_Draft_2brppa.mp3" length="18547200" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Prof. Frank Holz leads a panel discussion on a major leap forward in retinal prosthesis: the Prima system for geographic atrophy. Joined by Dr. Mahi Muqit and Prof. Lars-Olof Hattenbach, they explore how their extraordinary wireless subretinal implant is restoring visual perception in late-stage AMD. ]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1159</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>71</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 70: Highlights from the Euretina Congress 2025 in Paris.</title>
        <itunes:title>Episode 70: Highlights from the Euretina Congress 2025 in Paris.</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-70-highlights-from-the-euretina-congress-2025-in-paris/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-70-highlights-from-the-euretina-congress-2025-in-paris/#comments</comments>        <pubDate>Fri, 19 Sep 2025 12:21:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/1c736ac1-ac3f-37e5-89db-1dd87a64e29d</guid>
                                    <description><![CDATA[<p>In this episode, Profs. Lejla Vajzovic (USA), Sandrine Zweifel (Switzerland), and Heinrich Heimann (UK) reflect on a fantastic few days in Paris and share their highlights from the 2025 programme for you to watch back through the portal.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Profs. Lejla Vajzovic (USA), Sandrine Zweifel (Switzerland), and Heinrich Heimann (UK) reflect on a fantastic few days in Paris and share their highlights from the 2025 programme for you to watch back through the portal.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/n2fayhb59ub5fu84/Euretina_Ep709def0.mp3" length="47390827" type="audio/mpeg"/>
        <itunes:summary>In this episode, Profs. Lejla Vajzovic (USA), Sandrine Zweifel (Switzerland), and Heinrich Heimann (UK) reflect on a fantastic few days in Paris and share their highlights from the 2025 programme for you to watch back through the portal.</itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1454</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>70</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 69: Pioneering Retina: Prof. Ursula Schmidt-Erfurth on AI, AMD &amp; 25 Years of Euretina</title>
        <itunes:title>Episode 69: Pioneering Retina: Prof. Ursula Schmidt-Erfurth on AI, AMD &amp; 25 Years of Euretina</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-69-pioneering-retina-prof-ursula-schmidt-erfurth-on-ai-amd-25-years-of-euretina/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-69-pioneering-retina-prof-ursula-schmidt-erfurth-on-ai-amd-25-years-of-euretina/#comments</comments>        <pubDate>Sun, 31 Aug 2025 00:58:50 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/22934772-d66c-3e3a-8344-8638c3a4d745</guid>
                                    <description><![CDATA[<p>Euretina President Prof. Anat Loewenstein speaks with Prof. Ursula Schmidt-Erfurth, 25th Euretina Lecturer, about her groundbreaking career in retinal disease, from imaging innovations to AI-driven early detection. They discuss the EU-funded iScreen project, the future of AMD management, and the significance of two women presidents (past and present) as Euretina celebrates its 25th anniversary in Paris</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Euretina President Prof. Anat Loewenstein speaks with Prof. Ursula Schmidt-Erfurth, 25th Euretina Lecturer, about her groundbreaking career in retinal disease, from imaging innovations to AI-driven early detection. They discuss the EU-funded iScreen project, the future of AMD management, and the significance of two women presidents (past and present) as Euretina celebrates its 25th anniversary in Paris</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/bz4mbmmum3qbiq7r/Ep_69_Draft_298kpp.mp3" length="14789760" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Euretina President Prof. Anat Loewenstein speaks with Prof. Ursula Schmidt-Erfurth, 25th Euretina Lecturer, about her groundbreaking career in retinal disease, from imaging innovations to AI-driven early detection. They discuss the EU-funded iScreen project, the future of AMD management, and the significance of two women presidents (past and present) as Euretina celebrates its 25th anniversary in Paris]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>924</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>69</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 68: AI, Epidemiology &amp; Innovation: Prof. Korobelnik on the Future of Retina</title>
        <itunes:title>Episode 68: AI, Epidemiology &amp; Innovation: Prof. Korobelnik on the Future of Retina</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-68-ai-epidemiology-innovation-prof-korobelnik-on-the-future-of-retina/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-68-ai-epidemiology-innovation-prof-korobelnik-on-the-future-of-retina/#comments</comments>        <pubDate>Thu, 28 Aug 2025 21:49:19 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/461255f9-0716-33e6-b08b-17ff94418ad0</guid>
                                    <description><![CDATA[<p>Ahead of his Gisbert Richard Lecture at this year’s Euretina Congress in Paris, Prof. Jean-François Korobelnik joins Prof. Nicole Eter to reflect on a career at the forefront of retinal research. From surgical breakthroughs to his leadership of the E3 consortium, and his cautious optimism for AI, Prof. Korobelnik shares insights on past progress and future priorities in retina</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ahead of his Gisbert Richard Lecture at this year’s Euretina Congress in Paris, Prof. Jean-François Korobelnik joins Prof. Nicole Eter to reflect on a career at the forefront of retinal research. From surgical breakthroughs to his leadership of the E3 consortium, and his cautious optimism for AI, Prof. Korobelnik shares insights on past progress and future priorities in retina</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/bwnd98rtskugnx7a/Ep_68_Draft_28aioa.mp3" length="20291712" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ahead of his Gisbert Richard Lecture at this year’s Euretina Congress in Paris, Prof. Jean-François Korobelnik joins Prof. Nicole Eter to reflect on a career at the forefront of retinal research. From surgical breakthroughs to his leadership of the E3 consortium, and his cautious optimism for AI, Prof. Korobelnik shares insights on past progress and future priorities in retina]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1268</itunes:duration>
                <itunes:episode>68</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 67: Throwing Away Wisdom – Maria Berrocal on Saving Proven Treatments for PDR and Retinal Detachment</title>
        <itunes:title>Episode 67: Throwing Away Wisdom – Maria Berrocal on Saving Proven Treatments for PDR and Retinal Detachment</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-67-throwing-away-wisdom-%e2%80%93-maria-berrocal-on-saving-proven-treatments-for-pdr-and-retinal-detachment/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-67-throwing-away-wisdom-%e2%80%93-maria-berrocal-on-saving-proven-treatments-for-pdr-and-retinal-detachment/#comments</comments>        <pubDate>Fri, 15 Aug 2025 05:55:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/929e3fde-5521-341d-ad66-a434a79043f3</guid>
                                    <description><![CDATA[<p>Ahead of her Kreissig Award Lecture at the Euretina Congress in Paris, Professor Maria Berrocal (Puerto Rico) joins Euretina past president Alistair Laidlaw to discuss why time-tested treatments like PRP and scleral buckling still matter. They explore the risks of over-reliance on anti-VEGF in proliferative diabetic retinopathy, the decline in buckle training, and how chandelier techniques could revive it</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ahead of her Kreissig Award Lecture at the Euretina Congress in Paris, Professor Maria Berrocal (Puerto Rico) joins Euretina past president Alistair Laidlaw to discuss why time-tested treatments like PRP and scleral buckling still matter. They explore the risks of over-reliance on anti-VEGF in proliferative diabetic retinopathy, the decline in buckle training, and how chandelier techniques could revive it</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/z6pq7jg5egaghz8s/Episode_67_Draft_28wcux.mp3" length="21151104" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ahead of her Kreissig Award Lecture at the Euretina Congress in Paris, Professor Maria Berrocal (Puerto Rico) joins Euretina past president Alistair Laidlaw to discuss why time-tested treatments like PRP and scleral buckling still matter. They explore the risks of over-reliance on anti-VEGF in proliferative diabetic retinopathy, the decline in buckle training, and how chandelier techniques could revive it]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1321</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>67</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 66: A Holistic Approach? Patient Experience, Mental Health and Emotional Intelligence</title>
        <itunes:title>Episode 66: A Holistic Approach? Patient Experience, Mental Health and Emotional Intelligence</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-66-a-holistic-approach-patient-experience-mental-health-and-emotional-intelligence/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-66-a-holistic-approach-patient-experience-mental-health-and-emotional-intelligence/#comments</comments>        <pubDate>Fri, 01 Aug 2025 09:10:26 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/227fa07b-438e-3540-a848-74fb4dcc33d6</guid>
                                    <description><![CDATA[<p>In this thought-provoking episode, Professor Tariq Aslam and Retina International’s Avril Daly join Jonathan McCrea to explore the emotional and psychological dimensions of retinal disease. From the power of empathy in clinical care to the need for integrated mental health services, the discussion highlights why supporting patients beyond the medical chart is more vital than ever—especially in an AI-driven world.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this thought-provoking episode, Professor Tariq Aslam and Retina International’s Avril Daly join Jonathan McCrea to explore the emotional and psychological dimensions of retinal disease. From the power of empathy in clinical care to the need for integrated mental health services, the discussion highlights why supporting patients beyond the medical chart is more vital than ever—especially in an AI-driven world.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/cczzbe289t24wzrb/Ep_66_Draft_26244j.mp3" length="31782144" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this thought-provoking episode, Professor Tariq Aslam and Retina International’s Avril Daly join Jonathan McCrea to explore the emotional and psychological dimensions of retinal disease. From the power of empathy in clinical care to the need for integrated mental health services, the discussion highlights why supporting patients beyond the medical chart is more vital than ever—especially in an AI-driven world.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1986</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>66</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 65: Decoding White Spot Syndromes: Multimodal Imaging, Challenges &amp; Clinical Clarity</title>
        <itunes:title>Episode 65: Decoding White Spot Syndromes: Multimodal Imaging, Challenges &amp; Clinical Clarity</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-65-decoding-white-spot-syndromes-multimodal-imaging-challenges-clinical-clarity/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-65-decoding-white-spot-syndromes-multimodal-imaging-challenges-clinical-clarity/#comments</comments>        <pubDate>Tue, 15 Jul 2025 05:55:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/3dbe4ec2-b142-3c87-a31e-a3191eaff880</guid>
                                    <description><![CDATA[<p>Ahead of her Ophthalmologica Lecture at this year’s Euretina Congress, Dr. Maria Vittoria Cicinelli joins Professor Bahram Bodaghi to explore the evolving understanding of white spot syndromes. From classic presentations of punctate inner choroidopathy (PIC) to emerging imaging insights and therapeutic uncertainties, the conversation highlights unmet needs, research gaps, and practical implications for clinicians managing posterior uveitis</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ahead of her Ophthalmologica Lecture at this year’s Euretina Congress, Dr. Maria Vittoria Cicinelli joins Professor Bahram Bodaghi to explore the evolving understanding of white spot syndromes. From classic presentations of punctate inner choroidopathy (PIC) to emerging imaging insights and therapeutic uncertainties, the conversation highlights unmet needs, research gaps, and practical implications for clinicians managing posterior uveitis</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/rhv26f8fne3n9eee/Ep_65_Draft_287j99.mp3" length="19568640" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ahead of her Ophthalmologica Lecture at this year’s Euretina Congress, Dr. Maria Vittoria Cicinelli joins Professor Bahram Bodaghi to explore the evolving understanding of white spot syndromes. From classic presentations of punctate inner choroidopathy (PIC) to emerging imaging insights and therapeutic uncertainties, the conversation highlights unmet needs, research gaps, and practical implications for clinicians managing posterior uveitis]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1215</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>65</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 64: New Frontiers in Submacular Hemorrhage: Insights from Ophthalmologica</title>
        <itunes:title>Episode 64: New Frontiers in Submacular Hemorrhage: Insights from Ophthalmologica</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-64-a-tricky-treatment-of-submacular-hemorrhages/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-64-a-tricky-treatment-of-submacular-hemorrhages/#comments</comments>        <pubDate>Tue, 01 Jul 2025 17:21:17 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/5b7952e2-1861-365b-9cb4-9aff61658aa6</guid>
                                    <description><![CDATA[<p>In this episode, Prof. Martin Zinkernagel and Dr. Matias Iglicki spotlight Ophthalmologica’s new article collection on submacular hemorrhages. They explore key findings from four studies covering imaging, surgical strategies, and real-world outcomes, offering timely insights into managing this vision-threatening condition.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Prof. Martin Zinkernagel and Dr. Matias Iglicki spotlight Ophthalmologica’s new article collection on submacular hemorrhages. They explore key findings from four studies covering imaging, surgical strategies, and real-world outcomes, offering timely insights into managing this vision-threatening condition.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/cnyv2wy4m6qaphi7/Ep_64_Draft_26m8yu.mp3" length="34218624" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Prof. Martin Zinkernagel and Dr. Matias Iglicki spotlight Ophthalmologica’s new article collection on submacular hemorrhages. They explore key findings from four studies covering imaging, surgical strategies, and real-world outcomes, offering timely insights into managing this vision-threatening condition.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2138</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>64</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 63: Beyond Borders: Navigating Ophthalmology Fellowships Abroad</title>
        <itunes:title>Episode 63: Beyond Borders: Navigating Ophthalmology Fellowships Abroad</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-63-beyond-borders-navigating-ophthalmology-fellowships-abroad/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-63-beyond-borders-navigating-ophthalmology-fellowships-abroad/#comments</comments>        <pubDate>Tue, 17 Jun 2025 05:55:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/259ed665-a1a3-34c0-8e97-2595d2058465</guid>
                                    <description><![CDATA[<p>Ever considered broadening your professional horizons with an ophthalmology fellowship abroad? In this insightful episode, Dr. Peter Kiraly (Manchester Royal Eye Hospital) and Dr. Elon van Dijk (Leiden University Medical Center and Rotterdam Eye Hospital) share their personal journeys and practical advice from fellowships in the UK and Australia. Chaired by Jonathan McCrea</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ever considered broadening your professional horizons with an ophthalmology fellowship abroad? In this insightful episode, Dr. Peter Kiraly (Manchester Royal Eye Hospital) and Dr. Elon van Dijk (Leiden University Medical Center and Rotterdam Eye Hospital) share their personal journeys and practical advice from fellowships in the UK and Australia. Chaired by Jonathan McCrea</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/psif47gbnzze2qc8/Ep_63_Draft_2a8zye.mp3" length="27088896" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ever considered broadening your professional horizons with an ophthalmology fellowship abroad? In this insightful episode, Dr. Peter Kiraly (Manchester Royal Eye Hospital) and Dr. Elon van Dijk (Leiden University Medical Center and Rotterdam Eye Hospital) share their personal journeys and practical advice from fellowships in the UK and Australia. Chaired by Jonathan McCrea]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1693</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>63</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 62: Bridging the Gap: How to Make Smarter Ocular Oncology Referrals</title>
        <itunes:title>Episode 62: Bridging the Gap: How to Make Smarter Ocular Oncology Referrals</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-62-bridging-the-gap-how-to-make-smarter-ocular-oncology-referrals/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-62-bridging-the-gap-how-to-make-smarter-ocular-oncology-referrals/#comments</comments>        <pubDate>Thu, 05 Jun 2025 00:14:52 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/a4d9353d-0210-32df-a55c-1aef019325e3</guid>
                                    <description><![CDATA[<p>When should you refer and what should you include? Oncologists Hibba Quhill, Iwona Rospond-Kubiak, and Emine Kilic share practical, experience-based advice on improving referral pathways in ocular oncology. From triage strategies to imaging essentials, this episode covers what referring clinicians need to know to ensure timely and effective patient care</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>When should you refer and what should you include? Oncologists Hibba Quhill, Iwona Rospond-Kubiak, and Emine Kilic share practical, experience-based advice on improving referral pathways in ocular oncology. From triage strategies to imaging essentials, this episode covers what referring clinicians need to know to ensure timely and effective patient care</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/fbjctbbzgrq58873/Ep_62_Draft_2ady2p.mp3" length="21138432" type="audio/mpeg"/>
        <itunes:summary><![CDATA[When should you refer and what should you include? Oncologists Hibba Quhill, Iwona Rospond-Kubiak, and Emine Kilic share practical, experience-based advice on improving referral pathways in ocular oncology. From triage strategies to imaging essentials, this episode covers what referring clinicians need to know to ensure timely and effective patient care]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1321</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>62</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?</title>
        <itunes:title>Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-61-personalising-anti-vegf-treatment-in-neovascular-amd-does-phenotype-matter/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-61-personalising-anti-vegf-treatment-in-neovascular-amd-does-phenotype-matter/#comments</comments>        <pubDate>Wed, 30 Apr 2025 23:16:56 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/7c9f64f6-967a-30db-8998-24fccdfec466</guid>
                                    <description><![CDATA[<p>Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/w363knvvbciybmma/Ep_61_Draft_2avo4x.mp3" length="35231232" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2201</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>61</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 60: Pregnancy, Retina, and Uveitis: Striking the Balance in Challenging Cases</title>
        <itunes:title>Episode 60: Pregnancy, Retina, and Uveitis: Striking the Balance in Challenging Cases</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-60-pregnancy-retina-and-uveitis-striking-the-balance-in-challenging-cases/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-60-pregnancy-retina-and-uveitis-striking-the-balance-in-challenging-cases/#comments</comments>        <pubDate>Sun, 20 Apr 2025 23:19:50 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/ff73f6ad-af09-3a42-bef8-d3f547c154a8</guid>
                                    <description><![CDATA[<p>Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/49imgq48g3q2papa/Ep_60_Draft_29965z.mp3" length="36291456" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2268</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>60</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 59: Demystifying Hyperreflective Foci in AMD: From Histology to Imaging</title>
        <itunes:title>Episode 59: Demystifying Hyperreflective Foci in AMD: From Histology to Imaging</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-59-demystifying-hyperreflective-foci-in-amd-from-histology-to-imaging/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-59-demystifying-hyperreflective-foci-in-amd-from-histology-to-imaging/#comments</comments>        <pubDate>Wed, 02 Apr 2025 07:20:45 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/44f3fb30-f640-3a2f-9def-e8a64c172be2</guid>
                                    <description><![CDATA[<p>What are hyperreflective foci, and why do they matter in AMD? Prof. Stella Vujosevic is joined by Prof. Christine Curcio (University of Alabama at Birmingham) and Prof. Srinivas Sadda (Doheny Eye Institute, UCLA) to explore their significance—from donor eye histology to OCT imaging. They discuss key biomarkers, clinical implications, and how HRF can help guide treatment decisions in age-related macular degeneration</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>What are hyperreflective foci, and why do they matter in AMD? Prof. Stella Vujosevic is joined by Prof. Christine Curcio (University of Alabama at Birmingham) and Prof. Srinivas Sadda (Doheny Eye Institute, UCLA) to explore their significance—from donor eye histology to OCT imaging. They discuss key biomarkers, clinical implications, and how HRF can help guide treatment decisions in age-related macular degeneration</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/y363c3dng4td2dp2/Ep_59_Draft_2a8s35.mp3" length="27892992" type="audio/mpeg"/>
        <itunes:summary><![CDATA[What are hyperreflective foci, and why do they matter in AMD? Prof. Stella Vujosevic is joined by Prof. Christine Curcio (University of Alabama at Birmingham) and Prof. Srinivas Sadda (Doheny Eye Institute, UCLA) to explore their significance—from donor eye histology to OCT imaging. They discuss key biomarkers, clinical implications, and how HRF can help guide treatment decisions in age-related macular degeneration]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1743</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>59</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 58: Understanding Central Serous Chorioretinopathy: Insights, Challenges, and Future Directions</title>
        <itunes:title>Episode 58: Understanding Central Serous Chorioretinopathy: Insights, Challenges, and Future Directions</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-58-understanding-central-serous-chorioretinopathy-insights-challenges-and-future-directions/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-58-understanding-central-serous-chorioretinopathy-insights-challenges-and-future-directions/#comments</comments>        <pubDate>Tue, 18 Mar 2025 06:06:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/3b6711c4-6389-377e-9b7e-d45ccea9ae1b</guid>
                                    <description><![CDATA[<p>What causes central serous chorioretinopathy (CSC), and how should it be managed? In this episode, experts Camiel Boon, Sobha Sivaprasad, and Gemmy Cheung discuss the latest insights into CSC and the pachychoroid spectrum, including new imaging findings, risk factors, and treatment options like PDT, laser, and anti-VEGF</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>What causes central serous chorioretinopathy (CSC), and how should it be managed? In this episode, experts Camiel Boon, Sobha Sivaprasad, and Gemmy Cheung discuss the latest insights into CSC and the pachychoroid spectrum, including new imaging findings, risk factors, and treatment options like PDT, laser, and anti-VEGF</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/m4cdsuuei99rib7r/Ep_58_Draft_29mvlc.mp3" length="35913600" type="audio/mpeg"/>
        <itunes:summary><![CDATA[What causes central serous chorioretinopathy (CSC), and how should it be managed? In this episode, experts Camiel Boon, Sobha Sivaprasad, and Gemmy Cheung discuss the latest insights into CSC and the pachychoroid spectrum, including new imaging findings, risk factors, and treatment options like PDT, laser, and anti-VEGF]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2244</itunes:duration>
                <itunes:episode>58</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 57: Advancing Uveal Melanoma Treatment: Current Strategies and Future Directions</title>
        <itunes:title>Episode 57: Advancing Uveal Melanoma Treatment: Current Strategies and Future Directions</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-57-advancing-uveal-melanoma-treatment-current-strategies-and-future-directions/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-57-advancing-uveal-melanoma-treatment-current-strategies-and-future-directions/#comments</comments>        <pubDate>Mon, 03 Mar 2025 05:01:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/ccd99d84-39ec-3744-9ed3-ae25fa387e84</guid>
                                    <description><![CDATA[<p>Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/iym32tr3dhgz6zyb/Ep_57_Draft_27pcz0.mp3" length="32188416" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2011</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>57</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 56: Intraocular Tamponades and the Athens Special Focus Meeting</title>
        <itunes:title>Episode 56: Intraocular Tamponades and the Athens Special Focus Meeting</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-56-intraocular-tamponades-and-the-athens-special-focus-meeting/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-56-intraocular-tamponades-and-the-athens-special-focus-meeting/#comments</comments>        <pubDate>Tue, 11 Feb 2025 21:19:37 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/f36ea569-d934-3970-a68d-05dc1eba4db9</guid>
                                    <description><![CDATA[<p>In this episode, Chair Alistair Laidlaw (UK) chats to Mario Romano (Italy) and Stratos Gotzaridis (Greece) about some of the considerations and complications surrounding the use of intraocular tamponades. They also discuss the upcoming Special Focus Meeting in Athens which will centre on vitreoretinal surgery (VR)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Chair Alistair Laidlaw (UK) chats to Mario Romano (Italy) and Stratos Gotzaridis (Greece) about some of the considerations and complications surrounding the use of intraocular tamponades. They also discuss the upcoming Special Focus Meeting in Athens which will centre on vitreoretinal surgery (VR)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/yjtfmg3wmeyiar69/Ep_56_Draft_27rw64.mp3" length="21131520" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Chair Alistair Laidlaw (UK) chats to Mario Romano (Italy) and Stratos Gotzaridis (Greece) about some of the considerations and complications surrounding the use of intraocular tamponades. They also discuss the upcoming Special Focus Meeting in Athens which will centre on vitreoretinal surgery (VR)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1320</itunes:duration>
        <itunes:season>2</itunes:season>
        <itunes:episode>56</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 55: Highlights from the Euretina Congress 2024 Part 3: Arshad Khanani</title>
        <itunes:title>Episode 55: Highlights from the Euretina Congress 2024 Part 3: Arshad Khanani</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-55-highlights-from-the-euretina-congress-2024-part-3-arshad-khanani/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-55-highlights-from-the-euretina-congress-2024-part-3-arshad-khanani/#comments</comments>        <pubDate>Wed, 16 Oct 2024 05:54:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/0add290d-ddac-381c-9d81-d3f76011682b</guid>
                                    <description><![CDATA[<p>In this final episode of highlights from the Barcelona congress 2024, we’ll hear from Dr Arshad Khanani (USA) about clinical trials, long term-data and the importance of personalising the treatment to the patient</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this final episode of highlights from the Barcelona congress 2024, we’ll hear from Dr Arshad Khanani (USA) about clinical trials, long term-data and the importance of personalising the treatment to the patient</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/mv6kbkyzej6cbmfd/Ep_55_Draft_2bkkis.mp3" length="18316225" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this final episode of highlights from the Barcelona congress 2024, we’ll hear from Dr Arshad Khanani (USA) about clinical trials, long term-data and the importance of personalising the treatment to the patient]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1144</itunes:duration>
                <itunes:episode>55</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 54: Highlights from the Euretina Congress 2024 Part 2: Jean-Francois Korobelnik</title>
        <itunes:title>Episode 54: Highlights from the Euretina Congress 2024 Part 2: Jean-Francois Korobelnik</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-54-highlights-from-the-euretina-congress-2024-part-2-jean-francois-korobelnik/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-54-highlights-from-the-euretina-congress-2024-part-2-jean-francois-korobelnik/#comments</comments>        <pubDate>Wed, 09 Oct 2024 05:05:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/626b6180-3c1e-3ef3-b596-e24918840fee</guid>
                                    <description><![CDATA[<p>In this second episode looking at highlights from the Barcelona congress, we'll hear about AI and sustainability in ophthalmology from Prof Jean-Francois Korobelnik of University Hospital Bordeaux</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this second episode looking at highlights from the Barcelona congress, we'll hear about AI and sustainability in ophthalmology from Prof Jean-Francois Korobelnik of University Hospital Bordeaux</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/4z3fbvbshn3s4kk8/Ep_54_Draft_28lsh5.mp3" length="13346691" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this second episode looking at highlights from the Barcelona congress, we'll hear about AI and sustainability in ophthalmology from Prof Jean-Francois Korobelnik of University Hospital Bordeaux]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>834</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>54</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 53: Highlights from the Euretina Congress 2024 Part 1: Rumana Hussain</title>
        <itunes:title>Episode 53: Highlights from the Euretina Congress 2024 Part 1: Rumana Hussain</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-53-highlights-from-the-euretina-congress-2024-part-1-rumana-hussain/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-53-highlights-from-the-euretina-congress-2024-part-1-rumana-hussain/#comments</comments>        <pubDate>Fri, 04 Oct 2024 05:59:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/d5cd3091-1986-32da-a021-135c7ed9ed73</guid>
                                    <description><![CDATA[<p>Barcelona, We love you! Over the next few episodes, we'll be hearing from 3 different sub-specialty experts about their favourite picks from the excellent Euretina Congress this year. This week, we hear from Ms. Rumana Hussain, Consultant Ophthalmologist specialising in Ocular Oncology and VR surgery at Liverpool University Trust Foundation Hospitals</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Barcelona, We love you! Over the next few episodes, we'll be hearing from 3 different sub-specialty experts about their favourite picks from the excellent Euretina Congress this year. This week, we hear from Ms. Rumana Hussain, Consultant Ophthalmologist specialising in Ocular Oncology and VR surgery at Liverpool University Trust Foundation Hospitals</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/y838fqz2kemmuf6q/Ep_53_Draft_26032a.mp3" length="10907899" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Barcelona, We love you! Over the next few episodes, we'll be hearing from 3 different sub-specialty experts about their favourite picks from the excellent Euretina Congress this year. This week, we hear from Ms. Rumana Hussain, Consultant Ophthalmologist specialising in Ocular Oncology and VR surgery at Liverpool University Trust Foundation Hospitals]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>681</itunes:duration>
                <itunes:episode>53</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 52: The Ophthalmologica Lecture: Dr Yousif Subhi</title>
        <itunes:title>Episode 52: The Ophthalmologica Lecture: Dr Yousif Subhi</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-52-the-ophthalmologica-lecture-dr-yousif-subhi/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-52-the-ophthalmologica-lecture-dr-yousif-subhi/#comments</comments>        <pubDate>Mon, 02 Sep 2024 05:10:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/59f01e1f-cd94-30b5-8560-69a252f61bb0</guid>
                                    <description><![CDATA[<p>In this episode, Prof Nicole Eter (Germany) speaks with Dr Yousif Subhi, this year's Ophthalmologica lecture about his work in meta-analyses, evidence synthesis, determination of best-practice, and clinical research</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Prof Nicole Eter (Germany) speaks with Dr Yousif Subhi, this year's Ophthalmologica lecture about his work in meta-analyses, evidence synthesis, determination of best-practice, and clinical research</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/3i8btq6dfsda95u3/Ep_52_Draft_280qzy.mp3" length="15397198" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Prof Nicole Eter (Germany) speaks with Dr Yousif Subhi, this year's Ophthalmologica lecture about his work in meta-analyses, evidence synthesis, determination of best-practice, and clinical research]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>962</itunes:duration>
                <itunes:episode>52</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 51: The Euretina Lecture: Professor Ohno-Matsui</title>
        <itunes:title>Episode 51: The Euretina Lecture: Professor Ohno-Matsui</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-51-the-euretina-lecture-professor-ohno-matsui/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-51-the-euretina-lecture-professor-ohno-matsui/#comments</comments>        <pubDate>Mon, 19 Aug 2024 05:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/d9b4460d-4790-3211-ac53-8834dd43299b</guid>
                                    <description><![CDATA[<p>In this episode, Professor Kyoko Ohno-Matsui discusses advancements in imaging technologies and the management of myopic maculopathy ahead of her keynote lecture at the upcoming Euretina Congress in Barcelona. Chaired by Euretina President, Professor Anat Loewenstein</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Professor Kyoko Ohno-Matsui discusses advancements in imaging technologies and the management of myopic maculopathy ahead of her keynote lecture at the upcoming Euretina Congress in Barcelona. Chaired by Euretina President, Professor Anat Loewenstein</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/eendfxbaautnsaz4/Ep_51_Draft_270nt9.mp3" length="22499579" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Professor Kyoko Ohno-Matsui discusses advancements in imaging technologies and the management of myopic maculopathy ahead of her keynote lecture at the upcoming Euretina Congress in Barcelona. Chaired by Euretina President, Professor Anat Loewenstein]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1406</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>51</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 50: David Yorston on the Euretina/BEAVRS Database</title>
        <itunes:title>Episode 50: David Yorston on the Euretina/BEAVRS Database</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-50-david-yorston-on-the-euretinabeavrs-database/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-50-david-yorston-on-the-euretinabeavrs-database/#comments</comments>        <pubDate>Thu, 08 Aug 2024 17:45:11 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/a2aab84b-7d5f-3f17-920f-6682b98ec699</guid>
                                    <description><![CDATA[<p>Ahead of his prestigious Gisbert Richard lecture at this year's upcoming Euretina congress in Barcelona, David Yorston speaks to Euretina board member and former president Mr Alistair Laidlaw about his impressive career highlights and what we have learned so far from the BEAVRS Database</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Ahead of his prestigious Gisbert Richard lecture at this year's upcoming Euretina congress in Barcelona, David Yorston speaks to Euretina board member and former president Mr Alistair Laidlaw about his impressive career highlights and what we have learned so far from the BEAVRS Database</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/re3dh7rfdgh975nu/Ep_50_Draft_29hsgo.mp3" length="20540604" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Ahead of his prestigious Gisbert Richard lecture at this year's upcoming Euretina congress in Barcelona, David Yorston speaks to Euretina board member and former president Mr Alistair Laidlaw about his impressive career highlights and what we have learned so far from the BEAVRS Database]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1283</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>50</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 49: The challenges and opportunities for young retina specialists</title>
        <itunes:title>Episode 49: The challenges and opportunities for young retina specialists</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-49-the-challenges-and-opportunities-for-young-retina-specialists/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-49-the-challenges-and-opportunities-for-young-retina-specialists/#comments</comments>        <pubDate>Fri, 07 Jun 2024 05:00:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/43fc8a96-3daf-3f15-b860-f8fca26eb0de</guid>
                                    <description><![CDATA[<p>In this episode, Drs Kristina Pfau (Switzerland) and Elon Van Dijk (Netherlands) will talk about the importance of the YOURS committee, representing young retina specialists across Europe. They'll also discuss the opportunities that lie ahead and the challenges that are faced by early career clinicians and researchers</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Drs Kristina Pfau (Switzerland) and Elon Van Dijk (Netherlands) will talk about the importance of the YOURS committee, representing young retina specialists across Europe. They'll also discuss the opportunities that lie ahead and the challenges that are faced by early career clinicians and researchers</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/cgvwxmu7nc54yuq4/Ep_49_Draft_2brifv.mp3" length="20459520" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Drs Kristina Pfau (Switzerland) and Elon Van Dijk (Netherlands) will talk about the importance of the YOURS committee, representing young retina specialists across Europe. They'll also discuss the opportunities that lie ahead and the challenges that are faced by early career clinicians and researchers]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1278</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>49</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 48: Assessing Visual Deficits in Intermediate AMD</title>
        <itunes:title>Episode 48: Assessing Visual Deficits in Intermediate AMD</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-48-assessing-visual-deficits-in-intermediate-amd/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-48-assessing-visual-deficits-in-intermediate-amd/#comments</comments>        <pubDate>Thu, 02 May 2024 05:09:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/db34c5ff-d421-3b65-b517-2242337feca2</guid>
                                    <description><![CDATA[<p>In this podcast, Prof Frank Holz (Germany) discusses assessment of visual dysfunction in Intermediate AMD in the context of the Macustar trial with Dr Hannah Dunbar, Principal Optometrist at Moorfields and UCL</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, Prof Frank Holz (Germany) discusses assessment of visual dysfunction in Intermediate AMD in the context of the Macustar trial with Dr Hannah Dunbar, Principal Optometrist at Moorfields and UCL</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/2tg5qef6rqdc9mzg/Ep_48_Draft_26en7y.mp3" length="19451136" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, Prof Frank Holz (Germany) discusses assessment of visual dysfunction in Intermediate AMD in the context of the Macustar trial with Dr Hannah Dunbar, Principal Optometrist at Moorfields and UCL]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1215</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>48</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 47: Gut bacteria and eye disease?</title>
        <itunes:title>Episode 47: Gut bacteria and eye disease?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-47-gut-bacteria-and-eye-disease/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-47-gut-bacteria-and-eye-disease/#comments</comments>        <pubDate>Sun, 14 Apr 2024 22:13:24 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/082a4853-24f4-3f66-b716-63852d8d18e2</guid>
                                    <description><![CDATA[<p>In this podcast, Bart Leroy and Mark Pennesi discuss a provocative paper in Cell that seems to draw a link between bacteria normally found in our gut and retinal diseases such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). This episode was an initiative of EURETINA in collaboration with ERN-EYE (European Reference Network for Rare Eye Disease). </p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, Bart Leroy and Mark Pennesi discuss a provocative paper in Cell that seems to draw a link between bacteria normally found in our gut and retinal diseases such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). This episode was an initiative of EURETINA in collaboration with ERN-EYE (European Reference Network for Rare Eye Disease). </p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/fr2q4fsbpzrsdtip/Ep_47_Draft_270g0p.mp3" length="22912128" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, Bart Leroy and Mark Pennesi discuss a provocative paper in Cell that seems to draw a link between bacteria normally found in our gut and retinal diseases such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). This episode was an initiative of EURETINA in collaboration with ERN-EYE (European Reference Network for Rare Eye Disease). ]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1431</itunes:duration>
                <itunes:episode>47</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 46: How do you investigate your uveitis patient in 2024?</title>
        <itunes:title>Episode 46: How do you investigate your uveitis patient in 2024?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-46-how-do-you-investigate-your-uveitis-patient-in-2024/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-46-how-do-you-investigate-your-uveitis-patient-in-2024/#comments</comments>        <pubDate>Fri, 15 Mar 2024 06:01:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/92bb2769-5afa-3306-b489-472a18e2f9fe</guid>
                                    <description><![CDATA[<p>In this episode, Zohar Habot-Wilner (Israel) and Elisabetta Miserocchi (Italy) explore the key elements of clinical examination and how to approach work up when treating patients presenting with Uveitis. The discussion is chaired by Bahram Bodhagi (France)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Zohar Habot-Wilner (Israel) and Elisabetta Miserocchi (Italy) explore the key elements of clinical examination and how to approach work up when treating patients presenting with Uveitis. The discussion is chaired by Bahram Bodhagi (France)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/jy6vdx/Ep_46_Draft_285z2s.mp3" length="26920320" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Zohar Habot-Wilner (Israel) and Elisabetta Miserocchi (Italy) explore the key elements of clinical examination and how to approach work up when treating patients presenting with Uveitis. The discussion is chaired by Bahram Bodhagi (France)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1682</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>46</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 45: Robert J Johnston on Lab-Grown Retinas</title>
        <itunes:title>Episode 45: Robert J Johnston on Lab-Grown Retinas</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-45-robert-j-johnston-on-lab-grown-retinas/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-45-robert-j-johnston-on-lab-grown-retinas/#comments</comments>        <pubDate>Fri, 01 Mar 2024 12:38:39 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/19ed6a46-1011-32be-b045-d17de941d0ac</guid>
                                    <description><![CDATA[<p>In this episode, something a little different from the world of basic science: an interview with Bob J Johnston of Johns Hopkins who has been working with retinal organoids for the past decade. How are they made? What does industry think of them and will they one day become the default paradigm for retinal clinical research? Chaired by Jonathan McCrea</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, something a little different from the world of basic science: an interview with Bob J Johnston of Johns Hopkins who has been working with retinal organoids for the past decade. How are they made? What does industry think of them and will they one day become the default paradigm for retinal clinical research? Chaired by Jonathan McCrea</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/arr6js/Ep_43_Draft_3b05yu.mp3" length="18633216" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, something a little different from the world of basic science: an interview with Bob J Johnston of Johns Hopkins who has been working with retinal organoids for the past decade. How are they made? What does industry think of them and will they one day become the default paradigm for retinal clinical research? Chaired by Jonathan McCrea]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1164</itunes:duration>
                <itunes:episode>45</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 44: Second Eye Risk: Navigating Prophylaxis in Retinal Detachment, GRT, and Sticklers</title>
        <itunes:title>Episode 44: Second Eye Risk: Navigating Prophylaxis in Retinal Detachment, GRT, and Sticklers</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-44-second-eye-risk-navigating-prophylaxis-in-retinal-detachment-grt-and-sticklers/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-44-second-eye-risk-navigating-prophylaxis-in-retinal-detachment-grt-and-sticklers/#comments</comments>        <pubDate>Sun, 18 Feb 2024 23:36:22 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/6adb83c8-230b-3672-9dc5-4ae9bff703b2</guid>
                                    <description><![CDATA[<p>In this episode, we hear from an expert panel as they delve into the critical topic of second eye risk of retinal detachment (RD) and discuss approaches to prophylaxis. With Alistair Laidlaw (UK), Patricia Udaondo (Spain) and David Steel (UK)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we hear from an expert panel as they delve into the critical topic of second eye risk of retinal detachment (RD) and discuss approaches to prophylaxis. With Alistair Laidlaw (UK), Patricia Udaondo (Spain) and David Steel (UK)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/nxiw9u/Ep_45_Draft_27id7f.mp3" length="39712512" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we hear from an expert panel as they delve into the critical topic of second eye risk of retinal detachment (RD) and discuss approaches to prophylaxis. With Alistair Laidlaw (UK), Patricia Udaondo (Spain) and David Steel (UK)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2482</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>44</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 43: Spoilt for choice - the many treatments now available for AMD and DME</title>
        <itunes:title>Episode 43: Spoilt for choice - the many treatments now available for AMD and DME</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-43-spoilt-for-choice-the-many-treatments-now-available-for-amd-and-dme/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-43-spoilt-for-choice-the-many-treatments-now-available-for-amd-and-dme/#comments</comments>        <pubDate>Wed, 31 Jan 2024 23:23:49 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/f6e7dd3a-5220-3fde-a5ac-2b67860ef35e</guid>
                                    <description><![CDATA[<p>Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/qe4xs8/Ep_44_Draft_27exr2.mp3" length="21249024" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1328</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>43</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 42: A Guide to Radiation Maculopathy</title>
        <itunes:title>Episode 42: A Guide to Radiation Maculopathy</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-42-a-guide-to-radiation-maculopathy/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-42-a-guide-to-radiation-maculopathy/#comments</comments>        <pubDate>Mon, 15 Jan 2024 13:12:51 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/0c6b90af-d0b8-3148-8e6f-9067c9f82a18</guid>
                                    <description><![CDATA[<p>In this podcast episode, we will dig into the subject of radiation maculopathy, the most common complication following the irradiation of intraocular tumours, with a panel of ocular oncologists from across Europe: Hibba Quhill (UK), Iwona Rospond-Kubiak (Poland), Emine Kilic (Netherlands) and Raffaele Parrozzani (Italy).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast episode, we will dig into the subject of radiation maculopathy, the most common complication following the irradiation of intraocular tumours, with a panel of ocular oncologists from across Europe: Hibba Quhill (UK), Iwona Rospond-Kubiak (Poland), Emine Kilic (Netherlands) and Raffaele Parrozzani (Italy).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/5q6dju/Ep_42_Draft_2b3buo.mp3" length="21959424" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast episode, we will dig into the subject of radiation maculopathy, the most common complication following the irradiation of intraocular tumours, with a panel of ocular oncologists from across Europe: Hibba Quhill (UK), Iwona Rospond-Kubiak (Poland), Emine Kilic (Netherlands) and Raffaele Parrozzani (Italy).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1372</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>42</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 41: Ophthalmologica spotlight episode</title>
        <itunes:title>Episode 41: Ophthalmologica spotlight episode</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-41-ophthalmologica-spotlight-episode/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-41-ophthalmologica-spotlight-episode/#comments</comments>        <pubDate>Fri, 15 Dec 2023 06:05:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/90eacae4-758e-3154-90cf-0c99e9424f6a</guid>
                                    <description><![CDATA[<p>In this episode we look at two very interesting papers published in the latest editions of Ophthalmologica - Martin Busch presents his work on using microRNA as biomarkers for retinal disease and the panel discuss <a href='https://www.researchgate.net/scientific-contributions/Christina-K-Weisheit-2258647183?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InB1YmxpY2F0aW9uIiwicGFnZSI6InB1YmxpY2F0aW9uIn19'>Christina Weisheit</a>'s paper on Co2 emissions from the ophthalmic OR. Chaired by Patricia Udaondo, Matias Iglicki and Andreas Ebneter.</p>
<p> </p>
<p>Links to papers: </p>
<p><a href='https://karger.com/oph/article/246/3-4/169/861433/High-Impact-Actions-to-Reduce-the-Carbon-Dioxide'>https://karger.com/oph/article/246/3-4/169/861433/High-Impact-Actions-to-Reduce-the-Carbon-Dioxide</a></p>
<a href='https://karger.com/oph/article/246/3-4/227/861182/Circulating-MicroRNAs-as-Biomarker-for-Vessel?searchresult=1'>https://karger.com/oph/article/246/3-4/227/861182/Circulating-MicroRNAs-as-Biomarker-for-Vessel?searchresult=1</a>]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode we look at two very interesting papers published in the latest editions of Ophthalmologica - Martin Busch presents his work on using microRNA as biomarkers for retinal disease and the panel discuss <a href='https://www.researchgate.net/scientific-contributions/Christina-K-Weisheit-2258647183?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InB1YmxpY2F0aW9uIiwicGFnZSI6InB1YmxpY2F0aW9uIn19'>Christina Weisheit</a>'s paper on Co2 emissions from the ophthalmic OR. Chaired by Patricia Udaondo, Matias Iglicki and Andreas Ebneter.</p>
<p> </p>
<p>Links to papers: </p>
<p><a href='https://karger.com/oph/article/246/3-4/169/861433/High-Impact-Actions-to-Reduce-the-Carbon-Dioxide'>https://karger.com/oph/article/246/3-4/169/861433/High-Impact-Actions-to-Reduce-the-Carbon-Dioxide</a></p>
<a href='https://karger.com/oph/article/246/3-4/227/861182/Circulating-MicroRNAs-as-Biomarker-for-Vessel?searchresult=1'>https://karger.com/oph/article/246/3-4/227/861182/Circulating-MicroRNAs-as-Biomarker-for-Vessel?searchresult=1</a>]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/ju3rrn/Ep_41_Draft_2841jm.mp3" length="22965504" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode we look at two very interesting papers published in the latest editions of Ophthalmologica - Martin Busch presents his work on using microRNA as biomarkers for retinal disease and the panel discuss Christina Weisheit's paper on Co2 emissions from the ophthalmic OR. Chaired by Patricia Udaondo, Matias Iglicki and Andreas Ebneter.
 
Links to papers: 
https://karger.com/oph/article/246/3-4/169/861433/High-Impact-Actions-to-Reduce-the-Carbon-Dioxide
https://karger.com/oph/article/246/3-4/227/861182/Circulating-MicroRNAs-as-Biomarker-for-Vessel?searchresult=1]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1435</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>41</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 40: Prof David Huang: The co-inventor of OCT</title>
        <itunes:title>Episode 40: Prof David Huang: The co-inventor of OCT</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-40-prof-david-huang-the-co-inventor-of-oct/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-40-prof-david-huang-the-co-inventor-of-oct/#comments</comments>        <pubDate>Fri, 01 Dec 2023 06:05:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/34f555fa-8ec2-310d-9eaf-fb6c8f48abef</guid>
                                    <description><![CDATA[<p>Fresh from his exciting win of the Lasker Award - often dubbed the American Nobel Prize - Professor David Huang (USA) - the inventor of optical coherence tomography (OCT) - joins Prof Pearse Keane (UK) and Tunde Peto (Hungary/UK) to talk about how he and colleagues developed the technology and about the impact it has had on retinal medicine</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Fresh from his exciting win of the Lasker Award - often dubbed the American Nobel Prize - Professor David Huang (USA) - the inventor of optical coherence tomography (OCT) - joins Prof Pearse Keane (UK) and Tunde Peto (Hungary/UK) to talk about how he and colleagues developed the technology and about the impact it has had on retinal medicine</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/y5s4rh/Ep_40_Draft_2ade6f.mp3" length="25970112" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Fresh from his exciting win of the Lasker Award - often dubbed the American Nobel Prize - Professor David Huang (USA) - the inventor of optical coherence tomography (OCT) - joins Prof Pearse Keane (UK) and Tunde Peto (Hungary/UK) to talk about how he and colleagues developed the technology and about the impact it has had on retinal medicine]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1854</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>40</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 39: The Euretina Retinal Medicine Clinical Research Award</title>
        <itunes:title>Episode 39: The Euretina Retinal Medicine Clinical Research Award</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-39-the-euretina-retinal-medicine-clinical-research-award/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-39-the-euretina-retinal-medicine-clinical-research-award/#comments</comments>        <pubDate>Wed, 15 Nov 2023 06:55:47 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/5220a89b-c78f-38cf-824e-d93f6be68bbb</guid>
                                    <description><![CDATA[<p>As applications open for the Euretina Retinal Medicine Clinical Research Award, we hear about the award from Euretina EVP, Dara Conlon. We also gain interesting insights from previous winners Camiel Boon (Netherlands) and João Pedro Marques (Portugal) to see how the award has furthered their research.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>As applications open for the Euretina Retinal Medicine Clinical Research Award, we hear about the award from Euretina EVP, Dara Conlon. We also gain interesting insights from previous winners Camiel Boon (Netherlands) and João Pedro Marques (Portugal) to see how the award has furthered their research.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/tw6x7s/Ep_39_Draft_26c9tg.mp3" length="22579200" type="audio/mpeg"/>
        <itunes:summary><![CDATA[As applications open for the Euretina Retinal Medicine Clinical Research Award, we hear about the award from Euretina EVP, Dara Conlon. We also gain interesting insights from previous winners Camiel Boon (Netherlands) and João Pedro Marques (Portugal) to see how the award has furthered their research.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1612</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>39</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 38: Preview of Euretina Congress 2023</title>
        <itunes:title>Episode 38: Preview of Euretina Congress 2023</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-38-preview-of-euretina-congress-2023/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-38-preview-of-euretina-congress-2023/#comments</comments>        <pubDate>Fri, 29 Sep 2023 19:33:35 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/5d05a422-d968-3368-8341-b1c41cb94b9e</guid>
                                    <description><![CDATA[<p>In this podcast Euretina President, Mr Alistair Laidlaw and Euretina EVP Dara Conlon explore the highlights of this year's congress which is on track to be the biggest and most exciting meeting yet!</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast Euretina President, Mr Alistair Laidlaw and Euretina EVP Dara Conlon explore the highlights of this year's congress which is on track to be the biggest and most exciting meeting yet!</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/6m85h9/Ep_38_Draft_28a0b6.mp3" length="16032496" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast Euretina President, Mr Alistair Laidlaw and Euretina EVP Dara Conlon explore the highlights of this year's congress which is on track to be the biggest and most exciting meeting yet!]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1001</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>38</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 37: Blind Faith - How RP patients are being targeted with bad science across the world</title>
        <itunes:title>Episode 37: Blind Faith - How RP patients are being targeted with bad science across the world</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-37-blind-faith-how-rp-patients-are-being-targeted-with-bad-science-across-the-world/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-37-blind-faith-how-rp-patients-are-being-targeted-with-bad-science-across-the-world/#comments</comments>        <pubDate>Fri, 15 Sep 2023 05:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/7f2b9d6c-d6b3-3686-a2b5-c4a74f23f0a6</guid>
                                    <description><![CDATA[<p>In this episode, journalist Ramadan Younis and his executive producer Simon Cox tell us about their far-reaching BBC documentary. "Blind Faith" exposes the international practice of defrauding patients of Retinitis Pigmentosa with false hopes of treatment or cure with little or no evidence of efficacy. They are joined by Prof Robert McLaren of the University of Oxford, who consulted on the documentary and evaluated the scientific claims being made by bad actors in the programme. You can watch the documentary here: <a href='https://www.bbc.co.uk/programmes/p0f95ky3'>https://www.bbc.co.uk/programmes/p0f95ky3</a></p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, journalist Ramadan Younis and his executive producer Simon Cox tell us about their far-reaching BBC documentary. "Blind Faith" exposes the international practice of defrauding patients of Retinitis Pigmentosa with false hopes of treatment or cure with little or no evidence of efficacy. They are joined by Prof Robert McLaren of the University of Oxford, who consulted on the documentary and evaluated the scientific claims being made by bad actors in the programme. You can watch the documentary here: <a href='https://www.bbc.co.uk/programmes/p0f95ky3'>https://www.bbc.co.uk/programmes/p0f95ky3</a></p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/9rpqeu/Ep_37_Draft_3a0c8q.mp3" length="30960744" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, journalist Ramadan Younis and his executive producer Simon Cox tell us about their far-reaching BBC documentary. "Blind Faith" exposes the international practice of defrauding patients of Retinitis Pigmentosa with false hopes of treatment or cure with little or no evidence of efficacy. They are joined by Prof Robert McLaren of the University of Oxford, who consulted on the documentary and evaluated the scientific claims being made by bad actors in the programme. You can watch the documentary here: https://www.bbc.co.uk/programmes/p0f95ky3]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1934</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>37</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 36: The Ophthalmologica Lecture: Maximilian Pfau</title>
        <itunes:title>Episode 36: The Ophthalmologica Lecture: Maximilian Pfau</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-36-the-ophthalmologica-lecture-maximilian-pfau/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-36-the-ophthalmologica-lecture-maximilian-pfau/#comments</comments>        <pubDate>Fri, 01 Sep 2023 06:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/0d8406c0-239d-32cc-9b17-0533f93660b2</guid>
                                    <description><![CDATA[<p>In this episode, we’re going to dig into the subject of this year’s Ophtalmologica lecture which will be delivered on the Saturday afternoon at this year’s congress in Amsterdam. Professor Maximilan Pfau is a clinician with a specialism in AMD and Inherited Retinal diseases in the Department of Ophthalmology at the University Eye Hospital, Basel, Switzerland. He's joined by Editor in Chief of the Ophthalmologica Journal; Professor Martin Zinkernagel</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we’re going to dig into the subject of this year’s Ophtalmologica lecture which will be delivered on the Saturday afternoon at this year’s congress in Amsterdam. Professor Maximilan Pfau is a clinician with a specialism in AMD and Inherited Retinal diseases in the Department of Ophthalmology at the University Eye Hospital, Basel, Switzerland. He's joined by Editor in Chief of the Ophthalmologica Journal; Professor Martin Zinkernagel</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/q27ree/Ep_36_Draft_286d4c.mp3" length="18690000" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we’re going to dig into the subject of this year’s Ophtalmologica lecture which will be delivered on the Saturday afternoon at this year’s congress in Amsterdam. Professor Maximilan Pfau is a clinician with a specialism in AMD and Inherited Retinal diseases in the Department of Ophthalmology at the University Eye Hospital, Basel, Switzerland. He's joined by Editor in Chief of the Ophthalmologica Journal; Professor Martin Zinkernagel]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1334</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>36</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 35: Treating PCV and Pachychoroid in Different Populations</title>
        <itunes:title>Episode 35: Treating PCV and Pachychoroid in Different Populations</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-35-treating-pcv-and-pachychoroid-in-different-populations/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-35-treating-pcv-and-pachychoroid-in-different-populations/#comments</comments>        <pubDate>Tue, 15 Aug 2023 18:31:55 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/2ff873ea-4fba-35a6-a292-b05e5d1cd4f6</guid>
                                    <description><![CDATA[<p>In this episode, we head to Asia to hear from colleagues in Japan, Singapore and South Korea about their experiences treating PCV and Pachychoroid in different populations. The podcast is chaired by Prof Taiji Sakamoto (Japan) and Prof SeungYoung Yu (South Korea) who are joined by Prof Gemmy Cheung and Prof Adrian Koh (Singapore)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we head to Asia to hear from colleagues in Japan, Singapore and South Korea about their experiences treating PCV and Pachychoroid in different populations. The podcast is chaired by Prof Taiji Sakamoto (Japan) and Prof SeungYoung Yu (South Korea) who are joined by Prof Gemmy Cheung and Prof Adrian Koh (Singapore)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/8d3v94/Ep_35_Draft_2a2dzk.mp3" length="28784448" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we head to Asia to hear from colleagues in Japan, Singapore and South Korea about their experiences treating PCV and Pachychoroid in different populations. The podcast is chaired by Prof Taiji Sakamoto (Japan) and Prof SeungYoung Yu (South Korea) who are joined by Prof Gemmy Cheung and Prof Adrian Koh (Singapore)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2055</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>35</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 34: The Euretina Lecture: OncoVR</title>
        <itunes:title>Episode 34: The Euretina Lecture: OncoVR</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-34-the-euretina-lecture-oncovr/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-34-the-euretina-lecture-oncovr/#comments</comments>        <pubDate>Mon, 31 Jul 2023 06:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/4a9620f9-5ef9-38ca-bac6-00f4f34b7fba</guid>
                                    <description><![CDATA[<p>In this podcast, we hear from Euretina Keynote Bertil Damato (UK/Sweden) about his upcoming talk on OncoVR at the 2023 Euretina Congress. He is joined by colleague Carl Groenewald (UK) and Heinrich Heimann (Chair - UK)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, we hear from Euretina Keynote Bertil Damato (UK/Sweden) about his upcoming talk on OncoVR at the 2023 Euretina Congress. He is joined by colleague Carl Groenewald (UK) and Heinrich Heimann (Chair - UK)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/c2ai6b/Ep_34_Draft_2aamp9.mp3" length="22210944" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, we hear from Euretina Keynote Bertil Damato (UK/Sweden) about his upcoming talk on OncoVR at the 2023 Euretina Congress. He is joined by colleague Carl Groenewald (UK) and Heinrich Heimann (Chair - UK)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1586</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>34</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 33: The Euretina Innovation Summit - All You Need to Know</title>
        <itunes:title>Episode 33: The Euretina Innovation Summit - All You Need to Know</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-33-the-euretina-innovation-summit-all-you-need-to-know/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-33-the-euretina-innovation-summit-all-you-need-to-know/#comments</comments>        <pubDate>Mon, 03 Jul 2023 06:01:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/5d9ddd4d-9562-30c5-aec2-4749cfcc2a13</guid>
                                    <description><![CDATA[<p>In this podcast, we'll be hearing about an exciting new event taking
place in Amsterdam at the Euretina Congress in October; the inaugural
Euretina Innovation Summit (EIS). Kourous Rezaei (USA) and Anat
Loewenstein (Israel) - two members of the organising committee - will
discuss the programme and motivation behind the event with chair Frank
G Holz (Germany)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, we'll be hearing about an exciting new event taking<br>
place in Amsterdam at the Euretina Congress in October; the inaugural<br>
Euretina Innovation Summit (EIS). Kourous Rezaei (USA) and Anat<br>
Loewenstein (Israel) - two members of the organising committee - will<br>
discuss the programme and motivation behind the event with chair Frank<br>
G Holz (Germany)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/2jwtpx/Ep_33_Draft_2b3rxu.mp3" length="15394848" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, we'll be hearing about an exciting new event takingplace in Amsterdam at the Euretina Congress in October; the inauguralEuretina Innovation Summit (EIS). Kourous Rezaei (USA) and AnatLoewenstein (Israel) - two members of the organising committee - willdiscuss the programme and motivation behind the event with chair FrankG Holz (Germany)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1099</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>33</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 32: Macular Holes and Glaucoma in Myopia</title>
        <itunes:title>Episode 32: Macular Holes and Glaucoma in Myopia</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-32-macular-holes-and-glaucoma-in-myopia/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-32-macular-holes-and-glaucoma-in-myopia/#comments</comments>        <pubDate>Thu, 15 Jun 2023 02:22:54 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/6132c55c-592d-324b-9238-447766d43bad</guid>
                                    <description><![CDATA[<p>In this podcast, we’ll explore two areas in the subspecialty of myopia: Aude Couturier will share her expertise in macular holes and Dr Yves Lachkar will discuss glaucoma in highly myopic patients. Chaired by David Gaucher and Jost Jonas</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, we’ll explore two areas in the subspecialty of myopia: Aude Couturier will share her expertise in macular holes and Dr Yves Lachkar will discuss glaucoma in highly myopic patients. Chaired by David Gaucher and Jost Jonas</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/5tv8xb/Ep_32_Draft_2a8rhd.mp3" length="19434912" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, we’ll explore two areas in the subspecialty of myopia: Aude Couturier will share her expertise in macular holes and Dr Yves Lachkar will discuss glaucoma in highly myopic patients. Chaired by David Gaucher and Jost Jonas]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1388</itunes:duration>
                <itunes:episode>32</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 31: Featured studies from the Ophthalmologica journal</title>
        <itunes:title>Episode 31: Featured studies from the Ophthalmologica journal</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-31-featured-studies-from-the-ophthalmologica-journal/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-31-featured-studies-from-the-ophthalmologica-journal/#comments</comments>        <pubDate>Thu, 18 May 2023 03:33:42 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/71d0a100-2489-35f5-bf58-6e46fdf16e18</guid>
                                    <description><![CDATA[<p>In this episode, Editor in Chief at Ophthalmologica, Professor Martin Zinkernagel discusses two featured papers from Euretina’s official journal. The first paper discussed covers choroiditis and the second covers effective treatment regimen in macular degeneration. Faculty are Dr Jeannette Ossewaarde-van Norel and Evianne de Groot (University Medical Center Utrecht) and Mathis Thibaud, Red Cross University Hospital, Lyon</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Editor in Chief at Ophthalmologica, Professor Martin Zinkernagel discusses two featured papers from Euretina’s official journal. The first paper discussed covers choroiditis and the second covers effective treatment regimen in macular degeneration. Faculty are Dr Jeannette Ossewaarde-van Norel and Evianne de Groot (University Medical Center Utrecht) and Mathis Thibaud, Red Cross University Hospital, Lyon</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/piun6m/Ep_31_Draft_2adwy5.mp3" length="26969376" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Editor in Chief at Ophthalmologica, Professor Martin Zinkernagel discusses two featured papers from Euretina’s official journal. The first paper discussed covers choroiditis and the second covers effective treatment regimen in macular degeneration. Faculty are Dr Jeannette Ossewaarde-van Norel and Evianne de Groot (University Medical Center Utrecht) and Mathis Thibaud, Red Cross University Hospital, Lyon]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1926</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>31</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 30: Intraocular Lymphoma: An Explainer</title>
        <itunes:title>Episode 30: Intraocular Lymphoma: An Explainer</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-30-intraocular-lynphoma-an-explainer/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-30-intraocular-lynphoma-an-explainer/#comments</comments>        <pubDate>Tue, 02 May 2023 03:39:35 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/e31baade-9170-3533-b5ad-981adc3740c4</guid>
                                    <description><![CDATA[<p>In this episode, we explore how to diagnose and treat intraocular lymphoma with a panel of leading retinal surgeons and oncologists. Dr Hibba Quhill chairs the discussion with Professors Carlos Pavesio and Mandeep Sagoo from Moorfields Eye Hospital, London.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we explore how to diagnose and treat intraocular lymphoma with a panel of leading retinal surgeons and oncologists. Dr Hibba Quhill chairs the discussion with Professors Carlos Pavesio and Mandeep Sagoo from Moorfields Eye Hospital, London.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/umdzyt/Ep_30_Draft_2aebwa.mp3" length="28259952" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we explore how to diagnose and treat intraocular lymphoma with a panel of leading retinal surgeons and oncologists. Dr Hibba Quhill chairs the discussion with Professors Carlos Pavesio and Mandeep Sagoo from Moorfields Eye Hospital, London.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2018</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>30</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 29: How to get published in Euretina’s Journal, Ophthalmologica</title>
        <itunes:title>Episode 29: How to get published in Euretina’s Journal, Ophthalmologica</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-29-how-to-get-published-in-euretina-s-journal-ophthalmologica/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-29-how-to-get-published-in-euretina-s-journal-ophthalmologica/#comments</comments>        <pubDate>Fri, 14 Apr 2023 16:26:44 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/c5a47f76-9c67-3c41-b717-273e396906d0</guid>
                                    <description><![CDATA[<p>In this episode, we will hear all of the tips and tricks to success when looking to submit your research to Ophthalmologica.</p>
<p>Faculty: Martin Zinkernagel (Ophthalmologica editors) and Marco Casola (Karger).</p>
<p>Chaired by Jonathan McCrea</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we will hear all of the tips and tricks to success when looking to submit your research to Ophthalmologica.</p>
<p>Faculty: Martin Zinkernagel (Ophthalmologica editors) and Marco Casola (Karger).</p>
<p>Chaired by Jonathan McCrea</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/wrn6e4/Ep_29_Draft_3b6ju3.mp3" length="18630864" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we will hear all of the tips and tricks to success when looking to submit your research to Ophthalmologica.
Faculty: Martin Zinkernagel (Ophthalmologica editors) and Marco Casola (Karger).
Chaired by Jonathan McCrea]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1330</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>29</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 28: Diabetic Retinopathy - the latest exciting developments from across the world</title>
        <itunes:title>Episode 28: Diabetic Retinopathy - the latest exciting developments from across the world</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-28-diabetic-retinopathy-the-latest-exciting-developments-from-across-the-world/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-28-diabetic-retinopathy-the-latest-exciting-developments-from-across-the-world/#comments</comments>        <pubDate>Thu, 30 Mar 2023 01:20:24 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/ea29c7e2-4aa9-3b86-83ee-b3ba2bd6a6ce</guid>
                                    <description><![CDATA[<p>In this episode, Edoardo Midena (Italy) chairs a discussion with four leading experts in Diabetic Retinopathy from across the world: Jakob Grauslund (Denmark), Carol Cheung (Hong Kong), Enrico Borrelli (Italy) and Daniel Ting (Singapore)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Edoardo Midena (Italy) chairs a discussion with four leading experts in Diabetic Retinopathy from across the world: Jakob Grauslund (Denmark), Carol Cheung (Hong Kong), Enrico Borrelli (Italy) and Daniel Ting (Singapore)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/ujsg4q/Ep_28_Draft_2999l3.mp3" length="36188880" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Edoardo Midena (Italy) chairs a discussion with four leading experts in Diabetic Retinopathy from across the world: Jakob Grauslund (Denmark), Carol Cheung (Hong Kong), Enrico Borrelli (Italy) and Daniel Ting (Singapore)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2584</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>28</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 27: What do we mean by ”macula-off” RRD ... and how soon should we act?</title>
        <itunes:title>Episode 27: What do we mean by ”macula-off” RRD ... and how soon should we act?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-27-what-do-we-mean-by-macula-off-rrd-and-how-soon-should-we-act/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-27-what-do-we-mean-by-macula-off-rrd-and-how-soon-should-we-act/#comments</comments>        <pubDate>Tue, 14 Mar 2023 22:30:58 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/8b2b70aa-a5f3-3ee1-8969-5f1d897515bd</guid>
                                    <description><![CDATA[<p>In this episode, Siegfried Priglinger (Germany) and Roxane Hillier (UK) take a look at treatment for macula-off RRD. They're joined by David Yorston (Scotland) and Julian Klaas (Germany) and will ask - how do we best define "macula-off" and when should we start treatment?</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Siegfried Priglinger (Germany) and Roxane Hillier (UK) take a look at treatment for macula-off RRD. They're joined by David Yorston (Scotland) and Julian Klaas (Germany) and will ask - how do we best define "macula-off" and when should we start treatment?</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/5krsxi/Ep_27_Draft_2819ew.mp3" length="28430640" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Siegfried Priglinger (Germany) and Roxane Hillier (UK) take a look at treatment for macula-off RRD. They're joined by David Yorston (Scotland) and Julian Klaas (Germany) and will ask - how do we best define "macula-off" and when should we start treatment?]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2030</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>27</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 26: Tackling Acute Retinal Necrosis in Patients</title>
        <itunes:title>Episode 26: Tackling Acute Retinal Necrosis in Patients</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-26-tackling-acute-retinal-necrosis-in-patients/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-26-tackling-acute-retinal-necrosis-in-patients/#comments</comments>        <pubDate>Wed, 01 Mar 2023 01:05:56 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/4038bc42-b234-3951-ade3-018f06b45a5c</guid>
                                    <description><![CDATA[<p>Treating rare diseases can sometimes be challenging due a the lack of literature. In this episode, Carlos Pavesio (UK) asks leading experts Sara Touhami (France) and Moncef Khairallah (Tunisia) about their approaches to the diagnosis and treatment of Acute Retinal Necrosis (ARN).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Treating rare diseases can sometimes be challenging due a the lack of literature. In this episode, Carlos Pavesio (UK) asks leading experts Sara Touhami (France) and Moncef Khairallah (Tunisia) about their approaches to the diagnosis and treatment of Acute Retinal Necrosis (ARN).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/fejejs/Ep_26_Draft_2a9jou.mp3" length="27284880" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Treating rare diseases can sometimes be challenging due a the lack of literature. In this episode, Carlos Pavesio (UK) asks leading experts Sara Touhami (France) and Moncef Khairallah (Tunisia) about their approaches to the diagnosis and treatment of Acute Retinal Necrosis (ARN).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1948</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>26</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 25: What individual patient data can tell us about treating macular holes</title>
        <itunes:title>Episode 25: What individual patient data can tell us about treating macular holes</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-25-what-individual-patient-data-can-tell-us-about-treating-macular-holes/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-25-what-individual-patient-data-can-tell-us-about-treating-macular-holes/#comments</comments>        <pubDate>Wed, 15 Feb 2023 05:32:43 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/24bc3c54-f8db-3b17-8c47-a07810cf254a</guid>
                                    <description><![CDATA[<p>In this podcast, David Steel tells Alistair Laidlaw what he's learned from zeroing in on individual patient data and how factors like posture and hole size affect his decision-making in the treatment of macular holes</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this podcast, David Steel tells Alistair Laidlaw what he's learned from zeroing in on individual patient data and how factors like posture and hole size affect his decision-making in the treatment of macular holes</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/v4i2f5/Ep_25_Draft_29fh12.mp3" length="25922736" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, David Steel tells Alistair Laidlaw what he's learned from zeroing in on individual patient data and how factors like posture and hole size affect his decision-making in the treatment of macular holes]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1851</itunes:duration>
                <itunes:episode>25</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 24: Five Years after Approval of Voretigene Neparvovec – What is The Future of Retinal Gene Therapy?</title>
        <itunes:title>Episode 24: Five Years after Approval of Voretigene Neparvovec – What is The Future of Retinal Gene Therapy?</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-24-five-years-after-approval-of-voretigene-neparvovec-%e2%80%93-what-is-the-future-of-retinal-gene-therapy/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-24-five-years-after-approval-of-voretigene-neparvovec-%e2%80%93-what-is-the-future-of-retinal-gene-therapy/#comments</comments>        <pubDate>Mon, 06 Feb 2023 08:08:11 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/f8598964-7138-3a55-a834-a0444d66935d</guid>
                                    <description><![CDATA[In this podcast, Mark Penessi is joined by Isabelle Audo and Bart Leroy to discuss the impact of Luxturna and how gene therapy products will affect the treatment of inherited retinal diseases (IRD) in the future.
 ]]></description>
                                                            <content:encoded><![CDATA[In this podcast, Mark Penessi is joined by Isabelle Audo and Bart Leroy to discuss the impact of Luxturna and how gene therapy products will affect the treatment of inherited retinal diseases (IRD) in the future.
 ]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/3t7rws/Ep_24_Draft_36nqxe.mp3" length="27606768" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, Mark Penessi is joined by Isabelle Audo and Bart Leroy to discuss the impact of Luxturna and how gene therapy products will affect the treatment of inherited retinal diseases (IRD) in the future.
 ]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1971</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>24</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 23: Everything You Need to Know About the New EBO-Euretina Exam</title>
        <itunes:title>Episode 23: Everything You Need to Know About the New EBO-Euretina Exam</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-23-everything-you-need-to-know-about-the-new-ebo-euretina-exam/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-23-everything-you-need-to-know-about-the-new-ebo-euretina-exam/#comments</comments>        <pubDate>Tue, 17 Jan 2023 08:44:18 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/a7f44b74-2af3-3782-9863-84dbc93b76f4</guid>
                                    <description><![CDATA[<p>In this episode, Euretina President Alistair Laidlaw chairs a discussion with Nicole Eter (München University Medical Centre) and Brendan Strong, Head of Education at Agenda about the new EBO examination.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Euretina President Alistair Laidlaw chairs a discussion with Nicole Eter (München University Medical Centre) and Brendan Strong, Head of Education at Agenda about the new EBO examination.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/ug9knn/Ep_23_Draft_2a1cct.mp3" length="15102864" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Euretina President Alistair Laidlaw chairs a discussion with Nicole Eter (München University Medical Centre) and Brendan Strong, Head of Education at Agenda about the new EBO examination.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1078</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>23</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 22: Women in Retina</title>
        <itunes:title>Episode 22: Women in Retina</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/women-in-retina/</link>
                    <comments>https://Euretinatalks.podbean.com/e/women-in-retina/#comments</comments>        <pubDate>Thu, 01 Dec 2022 23:22:25 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/68b93780-36f1-3fbb-ba1a-62df4d25f0d9</guid>
                                    <description><![CDATA[In this podcast, we hear from author and leadership coach Sally Helgesen, author of Why Women Rise about the challenges facing aspiring women leaders. The interview is followed by a discussion with Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland) about the Women in Retina programme and how to move the dial when it comes to equality of opportunity in medical research.
 
Guests: Sally Helgesen (Author, USA) Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland)]]></description>
                                                            <content:encoded><![CDATA[In this podcast, we hear from author and leadership coach Sally Helgesen, author of <em>Why Women Rise</em> about the challenges facing aspiring women leaders. The interview is followed by a discussion with Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland) about the Women in Retina programme and how to move the dial when it comes to equality of opportunity in medical research.
 
Guests: Sally Helgesen (Author, USA) Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland)]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/5twp9g/EP_22_Draft_39afml.mp3" length="39779376" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this podcast, we hear from author and leadership coach Sally Helgesen, author of Why Women Rise about the challenges facing aspiring women leaders. The interview is followed by a discussion with Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland) about the Women in Retina programme and how to move the dial when it comes to equality of opportunity in medical research.
 
Guests: Sally Helgesen (Author, USA) Prof Anat Loewenstein (Israel) and Dr Ruth Freeman (Science Foundation Ireland)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2841</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>22</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 21: What To Know About The Bad Guy In Myopia: Staphyloma</title>
        <itunes:title>Episode 21: What To Know About The Bad Guy In Myopia: Staphyloma</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-21-what-to-know-about-the-bad-guy-in-myopia-staphyloma/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-21-what-to-know-about-the-bad-guy-in-myopia-staphyloma/#comments</comments>        <pubDate>Thu, 17 Nov 2022 10:28:44 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/da4b0102-fa0e-3ec1-b792-e12a581111aa</guid>
                                    <description><![CDATA[<p dir="ltr">In this in-depth podcast, Euretina President-Elect Ramin Tadayoni (France) chairs a discussion with Kyoko Ohno Matsui (Japan) and David Gaucher (France) exploring everything you need to know when dealing with the “bad guy” in myopia - Staphyloma.</p>
<p> </p>
<p dir="ltr">Panel: Prof Ramin Tadayoni, University Of Paris Cite, Lariboisière, Saint Louis And Adolphe De Rothschild Foundation Hospitals, France</p>
<p dir="ltr">Kyoko Ohno Matsui Tokyo Medical And Dental University, Japan</p>
<p dir="ltr">David Gaucher Dept Of Ophthalmology, University Of Strasbourg, France</p>
]]></description>
                                                            <content:encoded><![CDATA[<p dir="ltr">In this in-depth podcast, Euretina President-Elect Ramin Tadayoni (France) chairs a discussion with Kyoko Ohno Matsui (Japan) and David Gaucher (France) exploring everything you need to know when dealing with the “bad guy” in myopia - Staphyloma.</p>
<p> </p>
<p dir="ltr">Panel: Prof Ramin Tadayoni, University Of Paris Cite, Lariboisière, Saint Louis And Adolphe De Rothschild Foundation Hospitals, France</p>
<p dir="ltr">Kyoko Ohno Matsui Tokyo Medical And Dental University, Japan</p>
<p dir="ltr">David Gaucher Dept Of Ophthalmology, University Of Strasbourg, France</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/vnwnww/EP_21_Draft_28utht.mp3" length="21150192" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this in-depth podcast, Euretina President-Elect Ramin Tadayoni (France) chairs a discussion with Kyoko Ohno Matsui (Japan) and David Gaucher (France) exploring everything you need to know when dealing with the “bad guy” in myopia - Staphyloma.
 
Panel: Prof Ramin Tadayoni, University Of Paris Cite, Lariboisière, Saint Louis And Adolphe De Rothschild Foundation Hospitals, France
Kyoko Ohno Matsui Tokyo Medical And Dental University, Japan
David Gaucher Dept Of Ophthalmology, University Of Strasbourg, France]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1510</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>21</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 20: A Deep Dive into the MOLES System</title>
        <itunes:title>Episode 20: A Deep Dive into the MOLES System</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-20-a-deep-dive-into-the-moles-system/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-20-a-deep-dive-into-the-moles-system/#comments</comments>        <pubDate>Thu, 03 Nov 2022 20:49:06 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/89b783d0-243b-31bc-85d0-68f4e3204d02</guid>
                                    <description><![CDATA[<p>In this episode, Hibba Quhill (UK) explores each of the components that make up the MOLES system used for management of melanocytic choroidal tumours with the system's originator, Bertil Damato (UK/Sweden).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Hibba Quhill (UK) explores each of the components that make up the MOLES system used for management of melanocytic choroidal tumours with the system's originator, Bertil Damato (UK/Sweden).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/8ffqri/Ep_20_Draft_291xz9.mp3" length="26765270" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Hibba Quhill (UK) explores each of the components that make up the MOLES system used for management of melanocytic choroidal tumours with the system's originator, Bertil Damato (UK/Sweden).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1672</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>20</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 19: Exploring the Data from the Derby and Oaks Trials</title>
        <itunes:title>Episode 19: Exploring the Data from the Derby and Oaks Trials</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-19-exploring-the-data-from-the-derby-and-oaks-trials/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-19-exploring-the-data-from-the-derby-and-oaks-trials/#comments</comments>        <pubDate>Thu, 20 Oct 2022 23:26:10 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/3497505d-b92c-3f53-aad4-3ee5475241fd</guid>
                                    <description><![CDATA[<p> In this episode we will look at the Derby and Oaks trials; two trials looking at geographic atrophy associated with AMD. The session is chaired by Professor Frank Holz (Germany), featuring Professors Adnan Tufail (UK) and Sandrine Zweifel (Switzerland).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p> In this episode we will look at the Derby and Oaks trials; two trials looking at geographic atrophy associated with AMD. The session is chaired by Professor Frank Holz (Germany), featuring Professors Adnan Tufail (UK) and Sandrine Zweifel (Switzerland).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/p7ue53/Ep_19_Draft_29mtc8.mp3" length="19382160" type="audio/mpeg"/>
        <itunes:summary><![CDATA[ In this episode we will look at the Derby and Oaks trials; two trials looking at geographic atrophy associated with AMD. The session is chaired by Professor Frank Holz (Germany), featuring Professors Adnan Tufail (UK) and Sandrine Zweifel (Switzerland).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1384</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>19</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 18: Highlights Continued: The EURETINA Sessions</title>
        <itunes:title>Episode 18: Highlights Continued: The EURETINA Sessions</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-18-highlights-continued-the-euretina-sessions/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-18-highlights-continued-the-euretina-sessions/#comments</comments>        <pubDate>Sat, 24 Sep 2022 16:42:26 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/70b475c3-e176-375c-9481-394526caa170</guid>
                                    <description><![CDATA[<p>Worried you missed out on some great content at EURETINA? Don't worry! In this episode, we look back on the best Euretina sessions from the Congress. Joining us to give us their highlights from Hamburg are: Alistair Laidlaw, Euretina President, Ramin Tadayoni (France) and Kourous Rezaei (USA)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Worried you missed out on some great content at EURETINA? Don't worry! In this episode, we look back on the best Euretina sessions from the Congress. Joining us to give us their highlights from Hamburg are: Alistair Laidlaw, Euretina President, Ramin Tadayoni (France) and Kourous Rezaei (USA)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/scyifi/Ep_18_Draft_271fy4.mp3" length="26316800" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Worried you missed out on some great content at EURETINA? Don't worry! In this episode, we look back on the best Euretina sessions from the Congress. Joining us to give us their highlights from Hamburg are: Alistair Laidlaw, Euretina President, Ramin Tadayoni (France) and Kourous Rezaei (USA)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1644</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>18</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 17: Highlights from Euretina Congress in Hamburg</title>
        <itunes:title>Episode 17: Highlights from Euretina Congress in Hamburg</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-17-highlights-from-euretina-congress-in-hamburg/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-17-highlights-from-euretina-congress-in-hamburg/#comments</comments>        <pubDate>Thu, 08 Sep 2022 02:26:58 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/041b8e71-3fd2-39d6-aa3e-ddcb5ec94d9b</guid>
                                    <description><![CDATA[<p>In this episode, we catch up with Professors Camiel Boon, Tunde Peto and Dr Patricia Udaondo (New University and Polytechnic Hospital La Fe, Valencia) fresh from an incredible event in Hamburg to hear all about their highlights of the congress. They'll share their standout sessions that you need to catch up on via the Euretina portal at <a href='http://www.euretina.org/'>www.euretina.org</a></p>
<p> </p>
<p dir="ltr">Euretina 2022 Hamburg highlights:</p>
<p> </p>
<p dir="ltr">Tunde Peto:</p>
<p dir="ltr">Euretina Lecture - Sobha Sivaprasad </p>
<p dir="ltr">Euretina Session 10: Inherited Retinal Diseases</p>
<p dir="ltr">Subspecialty Sessions - Euretina IRD ERN-EYE session</p>
<p> </p>
<p dir="ltr">Camiel Boon: </p>
<p dir="ltr">Subspecialty Sessions - Euretina IRD ERN-EYE session</p>
<p dir="ltr">Euretina Session 14 - CSC</p>
<p dir="ltr">World Retina Day - Singapore Society of Ophthalmology Session:</p>
<p> </p>
<p dir="ltr">Patricia Eduaondo: </p>
<p dir="ltr">Euretina session 4 - Vitreoretinal Surgery I: Management of silicone oil complications</p>
<p dir="ltr">Euretina session 8 - Late Breakings </p>
<p dir="ltr">Euretina session 15 - Vitreoretinal Surgery II</p>
<p dir="ltr">World Retina Day - Spanish Society of Retina and Vitreous (SERV)  Vitreoretinal surgery in complex trauma cases</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we catch up with Professors Camiel Boon, Tunde Peto and Dr Patricia Udaondo (New University and Polytechnic Hospital La Fe, Valencia) fresh from an incredible event in Hamburg to hear all about their highlights of the congress. They'll share their standout sessions that you need to catch up on via the Euretina portal at <a href='http://www.euretina.org/'>www.euretina.org</a></p>
<p> </p>
<p dir="ltr">Euretina 2022 Hamburg highlights:</p>
<p> </p>
<p dir="ltr">Tunde Peto:</p>
<p dir="ltr">Euretina Lecture - Sobha Sivaprasad </p>
<p dir="ltr">Euretina Session 10: Inherited Retinal Diseases</p>
<p dir="ltr">Subspecialty Sessions - Euretina IRD ERN-EYE session</p>
<p> </p>
<p dir="ltr">Camiel Boon: </p>
<p dir="ltr">Subspecialty Sessions - Euretina IRD ERN-EYE session</p>
<p dir="ltr">Euretina Session 14 - CSC</p>
<p dir="ltr">World Retina Day - Singapore Society of Ophthalmology Session:</p>
<p> </p>
<p dir="ltr">Patricia Eduaondo: </p>
<p dir="ltr">Euretina session 4 - Vitreoretinal Surgery I: Management of silicone oil complications</p>
<p dir="ltr">Euretina session 8 - Late Breakings </p>
<p dir="ltr">Euretina session 15 - Vitreoretinal Surgery II</p>
<p dir="ltr">World Retina Day - Spanish Society of Retina and Vitreous (SERV)  Vitreoretinal surgery in complex trauma cases</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/jtvi9e/Ep_17_Draft_2bkslw.mp3" length="23017012" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we catch up with Professors Camiel Boon, Tunde Peto and Dr Patricia Udaondo (New University and Polytechnic Hospital La Fe, Valencia) fresh from an incredible event in Hamburg to hear all about their highlights of the congress. They'll share their standout sessions that you need to catch up on via the Euretina portal at www.euretina.org
 
Euretina 2022 Hamburg highlights:
 
Tunde Peto:
Euretina Lecture - Sobha Sivaprasad 
Euretina Session 10: Inherited Retinal Diseases
Subspecialty Sessions - Euretina IRD ERN-EYE session
 
Camiel Boon: 
Subspecialty Sessions - Euretina IRD ERN-EYE session
Euretina Session 14 - CSC
World Retina Day - Singapore Society of Ophthalmology Session:
 
Patricia Eduaondo: 
Euretina session 4 - Vitreoretinal Surgery I: Management of silicone oil complications
Euretina session 8 - Late Breakings 
Euretina session 15 - Vitreoretinal Surgery II
World Retina Day - Spanish Society of Retina and Vitreous (SERV)  Vitreoretinal surgery in complex trauma cases]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1438</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>17</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 16: Euretina Speaker Spotlight: Prof Hiroko Terasaki and Dr Enrico Borrelli</title>
        <itunes:title>Episode 16: Euretina Speaker Spotlight: Prof Hiroko Terasaki and Dr Enrico Borrelli</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-16-euretina-speaker-spotlight-prof-hiroko-terasaki-and-dr-enrico-borelli/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-16-euretina-speaker-spotlight-prof-hiroko-terasaki-and-dr-enrico-borelli/#comments</comments>        <pubDate>Tue, 16 Aug 2022 21:54:48 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/36bf545c-c4c8-3e20-9b8c-114200fdd4e7</guid>
                                    <description><![CDATA[<p>In this episode, we will again hear from two of our keynote speakers at the Euretina congress in Hamburg this September. Prof Hiroko Terasaki (Japan) who will give the Kreissig Lecture on Sept 3rd at Euretina (interviewed by Professor Ramin Tadayoni, Euretina President Elect) and Dr Enrico Borrelli (Italy) who will give the Ophthalmologica lecture (interviewed by Prof Frank Holz, Bonn, former Euretina President).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we will again hear from two of our keynote speakers at the Euretina congress in Hamburg this September. Prof Hiroko Terasaki (Japan) who will give the Kreissig Lecture on Sept 3rd at Euretina (interviewed by Professor Ramin Tadayoni, Euretina President Elect) and Dr Enrico Borrelli (Italy) who will give the Ophthalmologica lecture (interviewed by Prof Frank Holz, Bonn, former Euretina President).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/udt4pg/Ep_16_Draft_2ame1o.mp3" length="19157159" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we will again hear from two of our keynote speakers at the Euretina congress in Hamburg this September. Prof Hiroko Terasaki (Japan) who will give the Kreissig Lecture on Sept 3rd at Euretina (interviewed by Professor Ramin Tadayoni, Euretina President Elect) and Dr Enrico Borrelli (Italy) who will give the Ophthalmologica lecture (interviewed by Prof Frank Holz, Bonn, former Euretina President).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1197</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>16</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 15: Euretina Congress Keynotes</title>
        <itunes:title>Episode 15: Euretina Congress Keynotes</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-15-euretina-congress-keynotes/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-15-euretina-congress-keynotes/#comments</comments>        <pubDate>Wed, 03 Aug 2022 23:19:26 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/e06662a4-57a3-3932-8639-c93107e5b6ab</guid>
                                    <description><![CDATA[<p>In this episode Euretina President Mr Alistair Laidlaw previews two of our keynote speakers from this year's Euretina Congress in Hamburg. He is joined by Professor Sobha Sivaprasad (UK) and Professor Catherine Creuzot-Garcher (France)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode Euretina President Mr Alistair Laidlaw previews two of our keynote speakers from this year's Euretina Congress in Hamburg. He is joined by Professor Sobha Sivaprasad (UK) and Professor Catherine Creuzot-Garcher (France)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/i2gve5/Ep_15_Draft_377603.mp3" length="20503406" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode Euretina President Mr Alistair Laidlaw previews two of our keynote speakers from this year's Euretina Congress in Hamburg. He is joined by Professor Sobha Sivaprasad (UK) and Professor Catherine Creuzot-Garcher (France)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1281</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>15</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Talking Euretina Summer Break</title>
        <itunes:title>Talking Euretina Summer Break</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/talking-euretina-summer-break/</link>
                    <comments>https://Euretinatalks.podbean.com/e/talking-euretina-summer-break/#comments</comments>        <pubDate>Mon, 25 Jul 2022 16:50:44 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/87d90b25-9145-3fef-a69e-3790fa69f250</guid>
                                    <description><![CDATA[<p>Talking Euretina is taking a short break but will be back in August</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Talking Euretina is taking a short break but will be back in August</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/7vfpsx/Talking_Euretina_Summer_Break7l81v.mp3" length="1967752" type="audio/mpeg"/>
        <itunes:summary><![CDATA[Talking Euretina is taking a short break but will be back in August]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>122</itunes:duration>
        <itunes:season>1</itunes:season>
                <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 14: Non-invasive Imaging in Diabetic Retinopathy and Other Retinal Diseases</title>
        <itunes:title>Episode 14: Non-invasive Imaging in Diabetic Retinopathy and Other Retinal Diseases</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-14-non-invasive-imaging-in-diabetic-retinopathy-and-other-retinal-diseases/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-14-non-invasive-imaging-in-diabetic-retinopathy-and-other-retinal-diseases/#comments</comments>        <pubDate>Thu, 30 Jun 2022 22:39:24 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/7f27cde0-e47b-31e3-bf98-7759f8f6ec94</guid>
                                    <description><![CDATA[<p>In this episode, we explore non-invasive imaging of retinal diseases in a discussion chaired by Dr Stela Vujosevic ( Italy). Our faculty are Dr Bianca Gerendas, Medical University of Vienna and Dr Amani Fawzi, Northwestern University of Chicago.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we explore non-invasive imaging of retinal diseases in a discussion chaired by Dr Stela Vujosevic ( Italy). Our faculty are Dr Bianca Gerendas, Medical University of Vienna and Dr Amani Fawzi, Northwestern University of Chicago.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/77a2fu/Ep_14_Draft_3aybaf.mp3" length="26213141" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we explore non-invasive imaging of retinal diseases in a discussion chaired by Dr Stela Vujosevic ( Italy). Our faculty are Dr Bianca Gerendas, Medical University of Vienna and Dr Amani Fawzi, Northwestern University of Chicago.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1872</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>14</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 13: Choroidal Naevi in Daily Practice: Imaging, Follow-ups and the MOLES System</title>
        <itunes:title>Episode 13: Choroidal Naevi in Daily Practice: Imaging, Follow-ups and the MOLES System</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-13-choroidal-naevi-in-daily-practice-imaging-follow-ups-and-the-moles-system/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-13-choroidal-naevi-in-daily-practice-imaging-follow-ups-and-the-moles-system/#comments</comments>        <pubDate>Thu, 16 Jun 2022 09:13:20 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/631c5d3e-5f9f-3d99-a166-3c1def1f40d4</guid>
                                    <description><![CDATA[<p dir="ltr">In this episode, we return to the topic of ocular oncology to explore choroidal naevi in daily practice, through Imaging, follow-ups and the MOLES system. This expert discussion is chaired by Heinrich Heimann who is joined by Prof Bertil Damato, Dr Rumana Hussain, Dr Iwona Rospond-Kubiak and Dr Jose Caminal.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p dir="ltr">In this episode, we return to the topic of ocular oncology to explore choroidal naevi in daily practice, through Imaging, follow-ups and the MOLES system. This expert discussion is chaired by Heinrich Heimann who is joined by Prof Bertil Damato, Dr Rumana Hussain, Dr Iwona Rospond-Kubiak and Dr Jose Caminal.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/28sb3n/Ep_13_Draft_2968f0.mp3" length="30877056" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we return to the topic of ocular oncology to explore choroidal naevi in daily practice, through Imaging, follow-ups and the MOLES system. This expert discussion is chaired by Heinrich Heimann who is joined by Prof Bertil Damato, Dr Rumana Hussain, Dr Iwona Rospond-Kubiak and Dr Jose Caminal.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1929</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>13</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 12: Journal Club - Subretinal Hemorrhages and the TIGER study</title>
        <itunes:title>Episode 12: Journal Club - Subretinal Hemorrhages and the TIGER study</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-12-journal-club-subretinal-hemmorhages-and-the-tiger-study/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-12-journal-club-subretinal-hemmorhages-and-the-tiger-study/#comments</comments>        <pubDate>Wed, 01 Jun 2022 18:05:36 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/42bd8b57-a3d6-3ae3-90db-989c461fe24f</guid>
                                    <description><![CDATA[<p>This Journal Club is all about subretinal hemorrhaging as we take a look at 2 relevant papers and hear the latest developments of the Euretina-sponsored TIGER Study. It is chaired by Professors Grazia Pertile (Sacro Cuore Hospital Negrar, Verona) and Siegfried Priglinger (LMU Munich).  They're joined by Professor Timothy Jackson (King’s College, London), Dr Emilia Maggio (Sacro Cuore Hospital Negrar, Verona) and Dr Saskia van Romunde (The Rotterdam Eye Hospital)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>This Journal Club is all about subretinal hemorrhaging as we take a look at 2 relevant papers and hear the latest developments of the Euretina-sponsored TIGER Study. It is chaired by Professors Grazia Pertile (Sacro Cuore Hospital Negrar, Verona) and Siegfried Priglinger (LMU Munich).  They're joined by Professor Timothy Jackson (King’s College, London), Dr Emilia Maggio (Sacro Cuore Hospital Negrar, Verona) and Dr Saskia van Romunde (The Rotterdam Eye Hospital)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/4pvcr2/Ep_12_Draft_2a4s9c.mp3" length="41442816" type="audio/mpeg"/>
        <itunes:summary><![CDATA[This Journal Club is all about subretinal hemorrhaging as we take a look at 2 relevant papers and hear the latest developments of the Euretina-sponsored TIGER Study. It is chaired by Professors Grazia Pertile (Sacro Cuore Hospital Negrar, Verona) and Siegfried Priglinger (LMU Munich).  They're joined by Professor Timothy Jackson (King’s College, London), Dr Emilia Maggio (Sacro Cuore Hospital Negrar, Verona) and Dr Saskia van Romunde (The Rotterdam Eye Hospital)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2590</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>12</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 11: Imaging and AMD - Pathology, Biomarkers and Big Data</title>
        <itunes:title>Episode 11: Imaging and AMD - Pathology, Biomarkers and Big Data</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-11-imaging-and-amd-pathology-biomarkers-and-big-data/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-11-imaging-and-amd-pathology-biomarkers-and-big-data/#comments</comments>        <pubDate>Mon, 16 May 2022 11:29:36 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/6c9ab630-a7b0-3d8f-b65a-2de0c1e37d2f</guid>
                                    <description><![CDATA[<p>In this episode, Professor Sandrine Zweifel (Switzerland) and Professor Adnan Tufail (UK) chair a discussion on how imaging has affected our understanding of AMD. They discuss the impact of new biomarkers and also explore the effect of big data on this field now and into the future. Contributing faculty are Professor Christine Curcio (USA), Professor K Bailey Freund (USA) and Professor Srinivas Sadda (USA).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Professor Sandrine Zweifel (Switzerland) and Professor Adnan Tufail (UK) chair a discussion on how imaging has affected our understanding of AMD. They discuss the impact of new biomarkers and also explore the effect of big data on this field now and into the future. Contributing faculty are Professor Christine Curcio (USA), Professor K Bailey Freund (USA) and Professor Srinivas Sadda (USA).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/hjsnik/Ep_11_Draft_2a7ul2.mp3" length="32366759" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Professor Sandrine Zweifel (Switzerland) and Professor Adnan Tufail (UK) chair a discussion on how imaging has affected our understanding of AMD. They discuss the impact of new biomarkers and also explore the effect of big data on this field now and into the future. Contributing faculty are Professor Christine Curcio (USA), Professor K Bailey Freund (USA) and Professor Srinivas Sadda (USA).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2022</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>11</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 10: Diagnosis and Management of Uveitic Macular Edema</title>
        <itunes:title>Episode 10: Diagnosis and Management of Uveitic Macular Edema</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-10-diagnosis-and-management-of-uveitic-macular-edema/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-10-diagnosis-and-management-of-uveitic-macular-edema/#comments</comments>        <pubDate>Sun, 01 May 2022 00:05:00 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/de5a4a70-a85a-3e5d-a549-2fb1e147f660</guid>
                                    <description><![CDATA[<p>In this episode, Carlos Pavesio (UK) and Sofia Androudi (Greece) share their experience and insights in the diagnosis and treatment of macular edema. Chaired by Bahram Bodaghi (France).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Carlos Pavesio (UK) and Sofia Androudi (Greece) share their experience and insights in the diagnosis and treatment of macular edema. Chaired by Bahram Bodaghi (France).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/h7tc2r/Ep_10_Draft_29fqho.mp3" length="37668571" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Carlos Pavesio (UK) and Sofia Androudi (Greece) share their experience and insights in the diagnosis and treatment of macular edema. Chaired by Bahram Bodaghi (France).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2354</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>10</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 9: The Importance of Data Storytelling with Brent Dykes</title>
        <itunes:title>Episode 9: The Importance of Data Storytelling with Brent Dykes</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-9-the-importance-of-data-storytelling-with-brent-dykes/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-9-the-importance-of-data-storytelling-with-brent-dykes/#comments</comments>        <pubDate>Wed, 20 Apr 2022 09:45:26 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/0f613b1f-39b6-307b-b9f1-dfb821fe88ca</guid>
                                    <description><![CDATA[<p>In this episode, we hear from Brent Dykes  about the importance of storytelling with data and how to implement it when communicating research. Brent is author of Effective Data Storytelling, founder of Analytics Hero and a regular contributor to Forbes.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we hear from Brent Dykes  about the importance of storytelling with data and how to implement it when communicating research. Brent is author of Effective Data Storytelling, founder of Analytics Hero and a regular contributor to Forbes.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/8zuxzf/TE_Ep_9.mp3" length="27670161" type="audio/mpeg"/>
        <itunes:summary>Brent Dykes on why and how we should implement data storytelling when communicating our research.</itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1383</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>9</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 8: The Euretina Mentorship Programme</title>
        <itunes:title>Episode 8: The Euretina Mentorship Programme</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-8-the-euretina-mentorship-programme/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-8-the-euretina-mentorship-programme/#comments</comments>        <pubDate>Wed, 30 Mar 2022 23:36:27 +0100</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/704ed6c8-409a-38f6-b672-9f932ed00777</guid>
                                    <description><![CDATA[<p>In this episode, we explore the benefits of the Euretina Mentorship Programme. Guests are programme mentor and Euretina Board member, Dr Patricia Udaondo and Dara Conlon, Euretina Executive Vice President.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, we explore the benefits of the Euretina Mentorship Programme. Guests are programme mentor and Euretina Board member, Dr Patricia Udaondo and Dara Conlon, Euretina Executive Vice President.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/eqthnc/Ep_8_Draft_298eew.mp3" length="9114018" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, we explore the benefits of the Euretina Mentorship Programme. Guests are programme mentor and Euretina Board member, Dr Patricia Udaondo and Dara Conlon, Euretina Executive Vice President.]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>569</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>8</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 7: Exploring the Faricimab Trials</title>
        <itunes:title>Episode 7: Exploring the Faricimab Trials</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-7-exploring-the-faricimab-trials/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-7-exploring-the-faricimab-trials/#comments</comments>        <pubDate>Tue, 15 Mar 2022 00:25:34 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/a336d396-1266-32c3-9184-58d29526fa9d</guid>
                                    <description><![CDATA[<p>In January, The Lancet journal published studies showing that across 4 trials, faricimab improved and maintained vision in two leading causes of vision loss and reduced time between treatments. In this episode, we examine the results and implications of the research in an expert discussion chaired by Prof Anat Loewenstein (Tel Aviv Medical Centre) and Prof Reinier Schlingemann (Amsterdam University and Jules Gonin). They are joined by Ramin Tadayoni (Paris University), Professor Sandrine Zweifel (University Hospital Zurich) and Professor Usha Chakravarthy (Queen's University Belfast)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In January, The Lancet journal published studies showing that across 4 trials, faricimab improved and maintained vision in two leading causes of vision loss and reduced time between treatments. In this episode, we examine the results and implications of the research in an expert discussion chaired by Prof Anat Loewenstein (Tel Aviv Medical Centre) and Prof Reinier Schlingemann (Amsterdam University and Jules Gonin). They are joined by Ramin Tadayoni (Paris University), Professor Sandrine Zweifel (University Hospital Zurich) and Professor Usha Chakravarthy (Queen's University Belfast)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/4varv8/Ep_7_Draft_36q96h.mp3" length="33380310" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In January, The Lancet journal published studies showing that across 4 trials, faricimab improved and maintained vision in two leading causes of vision loss and reduced time between treatments. In this episode, we examine the results and implications of the research in an expert discussion chaired by Prof Anat Loewenstein (Tel Aviv Medical Centre) and Prof Reinier Schlingemann (Amsterdam University and Jules Gonin). They are joined by Ramin Tadayoni (Paris University), Professor Sandrine Zweifel (University Hospital Zurich) and Professor Usha Chakravarthy (Queen's University Belfast)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2086</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>7</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 6: Exciting developments in the treatment of metastatic melanoma</title>
        <itunes:title>Episode 6: Exciting developments in the treatment of metastatic melanoma</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-6-metastatic-disease-in-uveal-melanoma/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-6-metastatic-disease-in-uveal-melanoma/#comments</comments>        <pubDate>Mon, 28 Feb 2022 23:57:13 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/e3729671-f227-3ed8-8c6d-885020acbed6</guid>
                                    <description><![CDATA[<p>In this episode, Professors Heinrich Heimann (Liverpool University Hospital) and Jens Kiilgaard (Copenhagen University Hospital) chair a conversation about metastatic disease in uveal melanoma and a newly approved treatment, Tebentafusp. They’re joined by Dr Joseph Sacco (Liverpool University Hospital) and Dr Mette Bagger (Copenhagen University Hospital)</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode, Professors Heinrich Heimann (Liverpool University Hospital) and Jens Kiilgaard (Copenhagen University Hospital) chair a conversation about metastatic disease in uveal melanoma and a newly approved treatment, Tebentafusp. They’re joined by Dr Joseph Sacco (Liverpool University Hospital) and Dr Mette Bagger (Copenhagen University Hospital)</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/7bq96a/Ep_6_Draft_2ays6h.mp3" length="36147618" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Professors Heinrich Heimann (Liverpool University Hospital) and Jens Kiilgaard (Copenhagen University Hospital) chair a conversation about metastatic disease in uveal melanoma and a newly approved treatment, Tebentafusp. They’re joined by Dr Joseph Sacco (Liverpool University Hospital) and Dr Mette Bagger (Copenhagen University Hospital)]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2259</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>6</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 5: Inherited Retinal Diseases</title>
        <itunes:title>Episode 5: Inherited Retinal Diseases</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode5-inherited-retinal-diseases/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode5-inherited-retinal-diseases/#comments</comments>        <pubDate>Mon, 14 Feb 2022 23:09:15 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/f12a2f78-6fe5-3018-a95e-e7fcfa9a6093</guid>
                                    <description><![CDATA[<p>In this episode on inherited retinal diseases, we explore issues related to genetic testing: when it's needed, how access differs globally and when to refer patients to super specialist IRD centres. The discussion is chaired by Professor Bart LeRoy (Belgium) and Professor Isabelle Audo (Sorbonne France) with Dr Rola Ba-Abbad (Saudi Arabia) and Prof Graeme Black (UK).</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this episode on inherited retinal diseases, we explore issues related to genetic testing: when it's needed, how access differs globally and when to refer patients to super specialist IRD centres. The discussion is chaired by Professor Bart LeRoy (Belgium) and Professor Isabelle Audo (Sorbonne France) with Dr Rola Ba-Abbad (Saudi Arabia) and Prof Graeme Black (UK).</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/gqkmy6/Ep_5_Draft_274qkd.mp3" length="38273832" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode on inherited retinal diseases, we explore issues related to genetic testing: when it's needed, how access differs globally and when to refer patients to super specialist IRD centres. The discussion is chaired by Professor Bart LeRoy (Belgium) and Professor Isabelle Audo (Sorbonne France) with Dr Rola Ba-Abbad (Saudi Arabia) and Prof Graeme Black (UK).]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2396</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>5</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 4: Journal Club - Retinal Imaging &amp; AI</title>
        <itunes:title>Episode 4: Journal Club - Retinal Imaging &amp; AI</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-4-journal-club-retinal-imaging-ai/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-4-journal-club-retinal-imaging-ai/#comments</comments>        <pubDate>Tue, 01 Feb 2022 00:05:00 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/563a1194-4b55-3d3e-9124-96da597ba3c6</guid>
                                    <description><![CDATA[In this Journal Club episode, Tunde Peto from Queen’s University, Belfast and Sebastian Wolf from Inselspital in Bern chair a discussion on key papers in retinal imaging and AI. First, Pearse Keane of University College London presents work on the use of AI in the detection of papilledema (1). Tariq Aslam from Manchester University then explores the issues arising from a 2021 paper comparing different algorithms in diabetic retinopathy screening (2).
<p> </p>
(1): <a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1917130'>https://www.nejm.org/doi/full/10.1056/NEJMoa1917130</a>
<p> </p>
(2): <a href='https://pubmed.ncbi.nlm.nih.gov/33402366'>https://pubmed.ncbi.nlm.nih.gov/33402366</a>]]></description>
                                                            <content:encoded><![CDATA[In this Journal Club episode, Tunde Peto from Queen’s University, Belfast and Sebastian Wolf from Inselspital in Bern chair a discussion on key papers in retinal imaging and AI. First, Pearse Keane of University College London presents work on the use of AI in the detection of papilledema (1). Tariq Aslam from Manchester University then explores the issues arising from a 2021 paper comparing different algorithms in diabetic retinopathy screening (2).
<p> </p>
(1): <a href='https://www.nejm.org/doi/full/10.1056/NEJMoa1917130'>https://www.nejm.org/doi/full/10.1056/NEJMoa1917130</a>
<p> </p>
(2): <a href='https://pubmed.ncbi.nlm.nih.gov/33402366'>https://pubmed.ncbi.nlm.nih.gov/33402366</a>]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/i5dqrs/Ep_4_Draft_38m47w.mp3" length="39276460" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this Journal Club episode, Tunde Peto from Queen’s University, Belfast and Sebastian Wolf from Inselspital in Bern chair a discussion on key papers in retinal imaging and AI. First, Pearse Keane of University College London presents work on the use of AI in the detection of papilledema (1). Tariq Aslam from Manchester University then explores the issues arising from a 2021 paper comparing different algorithms in diabetic retinopathy screening (2).
 
(1): https://www.nejm.org/doi/full/10.1056/NEJMoa1917130
 
(2): https://pubmed.ncbi.nlm.nih.gov/33402366]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2454</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>4</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 3: Hot Topics in Diabetic Retinopathy</title>
        <itunes:title>Episode 3: Hot Topics in Diabetic Retinopathy</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-3-hot-topics-in-diabetic-retinopathy/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-3-hot-topics-in-diabetic-retinopathy/#comments</comments>        <pubDate>Fri, 14 Jan 2022 19:01:34 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/6af9b5e1-4867-35c9-bd76-9e843a973a5e</guid>
                                    <description><![CDATA[In this episode, Professors Edoardo Midena (Padua University Hospital) and Reinier Schlingemann (Amsterdam UMC) chair a discussion around some of the hot topics in the subspecialty field of diabetic retinopathy. Joined by Professors Jennifer Sun (Joslin Diabetes Center, Harvard Medical School) and Jakob Grauslund (University of Southern Denmark), they discuss:
 

- The treatment of non-proliferative diabetic retinopathy with anti-VEGF intravitreal injections
 
- Faricimab, a new drug for the treatment of diabetic macular edema. The rationale and preliminary data
 
- Artificial intelligence in the screening of diabetic retinopathy: pearls and pitfalls
]]></description>
                                                            <content:encoded><![CDATA[In this episode, Professors Edoardo Midena (Padua University Hospital) and Reinier Schlingemann (Amsterdam UMC) chair a discussion around some of the hot topics in the subspecialty field of diabetic retinopathy. Joined by Professors Jennifer Sun (Joslin Diabetes Center, Harvard Medical School) and Jakob Grauslund (University of Southern Denmark), they discuss:
 

- The treatment of non-proliferative diabetic retinopathy with anti-VEGF intravitreal injections
 
- Faricimab, a new drug for the treatment of diabetic macular edema. The rationale and preliminary data
 
- Artificial intelligence in the screening of diabetic retinopathy: pearls and pitfalls
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/bdekb6/Ep_3_Draft_2aeb34.mp3" length="39237172" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this episode, Professors Edoardo Midena (Padua University Hospital) and Reinier Schlingemann (Amsterdam UMC) chair a discussion around some of the hot topics in the subspecialty field of diabetic retinopathy. Joined by Professors Jennifer Sun (Joslin Diabetes Center, Harvard Medical School) and Jakob Grauslund (University of Southern Denmark), they discuss:
 

- The treatment of non-proliferative diabetic retinopathy with anti-VEGF intravitreal injections
 
- Faricimab, a new drug for the treatment of diabetic macular edema. The rationale and preliminary data
 
- Artificial intelligence in the screening of diabetic retinopathy: pearls and pitfalls
]]></itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>2452</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>3</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 2: Journal Club - VR Surgery</title>
        <itunes:title>Episode 2: Journal Club - VR Surgery</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/episode-2-journal-club-vr-surgery/</link>
                    <comments>https://Euretinatalks.podbean.com/e/episode-2-journal-club-vr-surgery/#comments</comments>        <pubDate>Tue, 14 Dec 2021 22:15:55 +0000</pubDate>
        <guid isPermaLink="false">Euretinatalks.podbean.com/c3903dae-8dae-3524-b0a0-83f153bb4ba4</guid>
                                    <description><![CDATA[<p>In the first of our monthly Journal Clubs, Ferdinando Bottoni and Carsten Meyer present their publications on optic disc pit maculopathy and a retinal expansion technique for persistent macular holes respectively. A short synopisis of each paper is given below.</p>
<p>The papers were discussed with the authors by a panel chaired by David Steel, Grazia Pertile and Marta Figueroa.</p>
<p>Bottoni F, Cereda M, Secondi R, Bochicchio S, Staurenghi G. Vitrectomy for optic disc pit maculopathy: a long-term follow-up study. Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):675-682.</p>
<p>Synopsis: In a retrospective non-comparative study of patients with optic disc pit maculopathy treated with vitrectomy alone, complete resolution of fluid in and under the fovea was achieved in 8 of 10 eyes (80%) without additional treatment.  One additional patient experienced a retinal detachment requiring further surgery. In the successful cases macular detachment resolved in a mean of 14 months after surgery. Postoperative BCVA improved significantly from a mean of 0.63 logMAR compared to a preoperative mean of 0.27 logMAR.  Nine eyes (82%) had a postoperative BCVA of 0.5 or better.</p>
<p>The authors concluded that vitrectomy with induction of alone was a safe and successful therapeutic option for the treatment of optic disc pit maculopathy.</p>
<p><a href='https://pubmed.ncbi.nlm.nih.gov/29411099/'>Vitrectomy for optic disc pit maculopathy: a long-term follow-up study - PubMed (nih.gov)</a></p>
<p> </p>
<p>Meyer CH, Szurman P, Haritoglou C, Maier M, Wolf A, Lytvynchuk L, Priglinger S, Hillenkamp J, Wachtlin J, Becker M, Mennel S, Koss MJ. Application of subretinal fluid to close refractory full thickness macular holes: treatment strategies and primary outcome: APOSTEL study. Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2151-2161. </p>
<p>In a retrospective non-comparative study by 12 surgeons on 41 eyes with persistent macular holes, the authors reported on their initial surgical, anatomical and functional experience with a technique of retinal expansion by applying balanced saline solution underneath the edges of the holes to free up subretinal adhesions which they postulated had inhibited primary closure. The PMH were closed with this technique in 35 out of the 41 eyes (85%) at 6 weeks after surgery. The postoperative BCVA improved to 0.22 from 0.1 pre op. The application of SR-fluid was not associated with major intraoperative adverse effects. The authors concluded that the technique could achieve a fast and immediate anatomical closure in many cases without serious adverse events.</p>
<p><a href='https://pubmed.ncbi.nlm.nih.gov/32583283/'>Application of subretinal fluid to close refractory full thickness macular holes: treatment strategies and primary outcome: APOSTEL study - PubMed (nih.gov)</a></p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In the first of our monthly Journal Clubs, Ferdinando Bottoni and Carsten Meyer present their publications on optic disc pit maculopathy and a retinal expansion technique for persistent macular holes respectively. A short synopisis of each paper is given below.</p>
<p>The papers were discussed with the authors by a panel chaired by David Steel, Grazia Pertile and Marta Figueroa.</p>
<p>Bottoni F, Cereda M, Secondi R, Bochicchio S, Staurenghi G. Vitrectomy for optic disc pit maculopathy: a long-term follow-up study. Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):675-682.</p>
<p>Synopsis: In a retrospective non-comparative study of patients with optic disc pit maculopathy treated with vitrectomy alone, complete resolution of fluid in and under the fovea was achieved in 8 of 10 eyes (80%) without additional treatment.  One additional patient experienced a retinal detachment requiring further surgery. In the successful cases macular detachment resolved in a mean of 14 months after surgery. Postoperative BCVA improved significantly from a mean of 0.63 logMAR compared to a preoperative mean of 0.27 logMAR.  Nine eyes (82%) had a postoperative BCVA of 0.5 or better.</p>
<p>The authors concluded that vitrectomy with induction of alone was a safe and successful therapeutic option for the treatment of optic disc pit maculopathy.</p>
<p><a href='https://pubmed.ncbi.nlm.nih.gov/29411099/'>Vitrectomy for optic disc pit maculopathy: a long-term follow-up study - PubMed (nih.gov)</a></p>
<p> </p>
<p>Meyer CH, Szurman P, Haritoglou C, Maier M, Wolf A, Lytvynchuk L, Priglinger S, Hillenkamp J, Wachtlin J, Becker M, Mennel S, Koss MJ. Application of subretinal fluid to close refractory full thickness macular holes: treatment strategies and primary outcome: APOSTEL study. Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2151-2161. </p>
<p>In a retrospective non-comparative study by 12 surgeons on 41 eyes with persistent macular holes, the authors reported on their initial surgical, anatomical and functional experience with a technique of retinal expansion by applying balanced saline solution underneath the edges of the holes to free up subretinal adhesions which they postulated had inhibited primary closure. The PMH were closed with this technique in 35 out of the 41 eyes (85%) at 6 weeks after surgery. The postoperative BCVA improved to 0.22 from 0.1 pre op. The application of SR-fluid was not associated with major intraoperative adverse effects. The authors concluded that the technique could achieve a fast and immediate anatomical closure in many cases without serious adverse events.</p>
<p><a href='https://pubmed.ncbi.nlm.nih.gov/32583283/'>Application of subretinal fluid to close refractory full thickness macular holes: treatment strategies and primary outcome: APOSTEL study - PubMed (nih.gov)</a></p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/kpfbzt/Euretina_Pod_Ep_2_Final7rj14.mp3" length="48092928" type="audio/mpeg"/>
        <itunes:summary>In the first of our monthly Journal Clubs, Ferdinando Bottoni and Carsten Meyer present their publications on optic disc pit maculopathy and a retinal expansion technique for persistent macular holes, respectively. Chaired by David Steel, Grazia Pertile and Marta Figueroa.</itunes:summary>
        <itunes:author>Whipsmart Media</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>3005</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>2</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Episode 1: The Next Four Years</title>
        <itunes:title>Episode 1: The Next Four Years</itunes:title>
        <link>https://Euretinatalks.podbean.com/e/001-the-future-of-euretina/</link>
                    <comments>https://Euretinatalks.podbean.com/e/001-the-future-of-euretina/#comments</comments>        <pubDate>Wed, 01 Dec 2021 21:12:04 +0000</pubDate>
        <guid isPermaLink="false">jonathan77.podbean.com/ffba0718-141f-3a0b-bbea-6a7195cc40e4</guid>
                                    <description><![CDATA[<p>In this first episode, Euretina’s new president Alistair Laidlaw discusses the future strategy and vision of the society with president-elect Ramin Tadayoni and General Secretary Professor Anat Loewenstein.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In this first episode, Euretina’s new president Alistair Laidlaw discusses the future strategy and vision of the society with president-elect Ramin Tadayoni and General Secretary Professor Anat Loewenstein.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/v2kqwf/TalkingEuretinaE01_TheNextFourYears.mp3" length="23055171" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In this first episode, Euretina’s new president Alistair Laidlaw discusses the future strategy and vision of the society with president-elect Ramin Tadayoni and General Secretary Professor Anat Loewenstein.]]></itunes:summary>
        <itunes:author>Euretina</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1153</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>1</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
        <itunes:image href="https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog12977711/Euretina_Podcast_iTunes-Cover-with-logo-02_t94rky2.jpeg" />    </item>
</channel>
</rss>
